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ABSTRACT 
The bleomycins are a family of glycopeptide-derived antibiotics isolated from 
various Streptomyces species and have been the subject of much attention from the 
scientific community as a consequence of their antitumor activity. Bleomycin clinically 
and is an integral part of a number of combination chemotherapy regimens. It has 
previously been shown that bleomycin has the ability to selectively target tumor cells 
over their non-malignant counterparts.  
Pyrimidoblamic acid, the N-terminal metal ion binding domain of bleomycin is 
known to be the moiety that is responsible for O2 activation and the subsequent chemistry 
leading to DNA strand scission and overall antitumor activity. Chapter 1 describes 
bleomycin and related DNA targeting antitumor agents as well as the specific structural 
domains of bleomycin. Various structural analogues of pyrimidoblamic acid were 
synthesized and subsequently incorporated into their corresponding full deglycoBLM A6 
derivatives by utilizing a solid support. Their activity was measured using a pSP64 DNA 
plasmid relaxation assay and is summarized in Chapter 2. 
The specifics of bleomycin‒DNA interaction and kinetics were studied via 
surface plasmon resonance and are presented in Chapter 3. By utilizing carefully selected 
64-nucleotide DNA hairpins with variable 16-mer regions whose sequences showed 
strong binding in past selection studies, a kinetic profile was obtained for several BLMs 
for the first time since bleomycin was discovered in 1966. 
The disaccharide moiety of bleomycin has been previously shown to be a specific 
tumor cell targeting element comprised of L-gulose-D-mannose, especially between 
MCF-7 (breast cancer cells) and MCF-10A (“normal” breast cells). This phenomenon 
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was further investigated via fluorescence microscopy using multiple cancerous cell lines 
with matched “normal” counterparts and is fully described in Chapter 4. 
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Chapter 1 
 
1.01 Introduction 
 
 Cancer is a family of diseases for which there is currently no certain cure and one  
 
that has a global and devastating effect on its victims and their families; cancer claims  
 
millions of lives worldwide every single year.
1
 The need for selective chemotherapeutic  
 
agents for use in diagnostics, imaging and treatment of cancers has never been more  
 
critical and remains the subject of intense ongoing research efforts. Chemotherapeutic  
 
agents are compounds whose mechanisms involve inhibiting or perturbing normal  
 
cellular functions by targeting, for example, protein synthesis,
2
 cell division,
3
 and  
 
deoxyribonucleic acid (DNA) replication and transcription.
4
 DNA has shown to be an  
 
especially effective target for many classes of chemotherapeutic agents. This includes  
 
both intercalators, which work directly on DNA itself and groove binders (Figure 1.01),  
 
which allow for the disruption of critical DNA‒protein interactions during cell division.  
 
 
Figure 1.01 Schematic representation of DNA-chemotherapeutic interaction, A) 
intercalation; B) minor groove-binding
5 
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Bleomycin is a minor groove-binding agent and belongs to a unique class of  
 
chemotherapeutics. 
 
 The bleomycins (BLMs) are a family of glycopeptide-derived antibiotics  
 
originally isolated from a culture broth of Streptomyces verticillus species as its natural  
 
copper chelate.
6
 
 
Bleomycin was first isolated in 1966 by Umezawa and co-workers and  
 
has been studied extensively due to its antitumor activity.
7
 
 
Bleomycin is currently  
 
employed clinically, in The United States under the trade name Blenoxane and used in  
 
conjunction with other antitumor agents as part of standard combination chemotherapy  
 
regiments (ABVD, BEACOPP, etc). Blenoxane is a mixture of several congeners,  
 
consisting predominantly of bleomycins A2 (~60%) and B2 (~30%), that differ in structure  
 
solely at the C-terminus (Figure 1.02). In other parts of the world, including China,  
 
bleomycin is administered primarily as the single BLM A5 congener. 
 
 
Figure 1.02 BLMs A2, B2, A5 and A6 
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Bleomycin is used to treat a variety of malignancies, including squamous cell  
 
carcinomas, testicular cancers and Hodgkin’s lymphomas. One of the primary drawbacks  
 
of bleomycin therapy is the risk to patients for developing pulmonary fibrosis. The  
 
most logical explanation of this phenomenon is DNA cleavage by bleomycin that is  
 
oxygen dependent and thus much more likely to occur in  pulmonary tissue where oxygen  
 
availability is significantly higher than other tissues. Another possibility is that the  
 
polyamine side chain found primarily in BLMs A5 and A6 contribute to its pulmonary  
 
toxicity, as much simpler polyamines are well known to be toxic to lung tissue.
8
 Other  
 
structurally related glycopeptide antibiotics, such as the phleomycins (PLMs),  
 
zorbamycin (ZBM) or the tallysomycins (TLMs) (Figure 1.03) are known to exhibit  
 
antitumor activity in a similar way.
9,10
  
 
 
Figure 1.03 Structural comparisons of antitumor antibiotics: BLM A2 and B2, 
tallysomycin (TLM) S10B, phleomycin (PLM) D1, and zorbamycin (ZBM). Structural 
differences from the BLMs have been highlighted.
9 
 
 4   
  
In an effort to verify the exact structure of the BLMs and to study the specific  
 
mechanism of action of these antibiotics, the total synthesis of BLM A2 was completed  
 
by both the Hecht
11
 and Umezawa
12
  laboratories in 1982 and by the Boger laboratory in  
 
1994.
13
 However, it was not until 2000 when the Hecht group synthesized BLM using a  
 
solid-phase approach that an extensive BLM library could be realized. Following this  
 
discovery, a combinatorial library of 108 deglycoBLM analogues was created in 2003 
 
to further explore the mechanism of action and the structure-activity relationships (SAR)  
 
of BLM.
14 
 
The structure of bleomycin can be divided into four distinct regions; the N- 
 
terminal metal ion binding domain (also known as pyrimidoblamic acid), the C-terminal  
 
bithiazole DNA binding domain, the methylvalerate-threonine linker region and the  
 
disaccharide region (Figure 1.02).
 
In terms of function the metal ion binding domain  
 
pyrimidoblamic acid (PBA), is responsible for metal ion binding (and has demonstrated  
 
the ability to bind many first row transition metals including Fe, Cu, Co, Mn, Ni, Ru, V  
 
and Zn) as well as being responsible for oxygen activation.
15,16
 While in a clinical  
 
setting bleomycin is administered in its apo-form (metal free) but is believed to quickly  
 
coordinate with metals in vivo. Iron may be the most abundant cofactor available;  
 
accordingly Fe•BLM has been the most extensively studied metallobleomycin.12 Given  
 
the attention afforded to this metallobleomycin within the scientific community and  
 
literature, the arrangement of the ligands was a subject of much debate. Recently, Buda  
 
and coworkers published a computational model taking into consideration past  
 
experimental and multinuclear NMR evidence (Figure 1.04).
15 
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Figure 1.04 Model of the metal coordination domain of Fe(II)•BLM15 
 
Pyrimidoblamic acid has been well described as the primary metal chelating  
 
domain of bleomycin.
12,13,15,17-19 
 The equatorial ligands consist of the secondary amine of  
 
the β-aminoalanineamide moiety, the pyrimidine (N3), the imidazole ring (N5) and the  
 
amide nitrogen of the β-hydroxyhistidine. The axial ligands include the primary amine of  
 
the β-aminoalanineamide moiety and the oxygen atom of the carbamoyl group at the C3  
 
position of the mannose in the sugar moiety.  
 
 At the C-terminus of bleomycin, there is a bithiazole moiety linked to a variety of  
 
functionalized side chains shown in Figure 1.02. Each of these side chains contains an  
 
inherent positive charge (BLM A2, BLM B2) or a polyamine chain that is positively  
 
charged in physiological environments (BLM A5, BLM A6). This structural property  
 
allows for strong interaction between BLM and the negatively charged phosphate  
 
backbone of nucleic acids thereby facilitating the binding of the bithiazole moiety into  
 
the minor groove of DNA and subsequent cleavage. 
 
 To further understand the interaction between the C-terminus of bleomycin and  
 
DNA binding, bithiazole analogues have been synthesized, incorporated into  
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deglycobleomycin and studied.
20 
Several monothiazole analogues were prepared in  
 
which one of the two thiazole heterocycles was substituted with S-methyl-L-cysteine  
 
(Figure 2.05). 
 
Figure 1.05 DeglycoBLM congeners containing monothiazole analogues
20,21 
 
 In this study it was found that the deglycobleomycin A2 analogues altered in the  
 
bithiazole moiety had a substantial decrease in their ability to cleave DNA. Additionally  
 
the analogues showed a lack of sequence selective selectivity. It was concluded that this  
 
dramatic decline in activity was due to inefficient DNA binding and suggested the  
 
bithiazole moiety was necessary for sequence-selective DNA cleavage. Further evidence  
 
of this was shown by Hecht and coworkers, where a trithiazole moiety (Figure 1.05)  
 
exhibited altered sequence selectivity from the primary 5ʹ-GC-3ʹ patterns to less  
 
commonly observed 5ʹ-GT-3ʹ.22  
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Figure 1.06. DeglycoBLM congener containing a trithiazole moiety
22 
 
 Between the N-terminal metal ion binding domain (PBA) and the C-terminal  
 
DNA binding domain is a linker region composed of L-threonine and methylvalerate  
 
moieties. Other than simply acting as a tether between the N- and C-termini of BLM, the  
 
complete functionality of the linker region was not fully understood until nearly a decade  
 
after bleomycin was isolated.
23.24 
In a previous by Boger and coworkers, the linker  
 
region was studied by substituting a peptide chain that lacked the peripheral substituents  
 
(Figure 2.06).
25
 
 
 
 
Figure 2.07 A) BLM A2 B) (deglyco)BLM A2 altered in the linker region
26 
 
 It was found that the BLM A2 congener with the altered linker region  
 8   
  
 
displayed significantly lower cleavage activity when compared with deglycoBLM A2. In  
 
a study in the Hecht laboratory, a similar result was also seen when threonine was  
 
replaced with an (oligo)glycine spacer (one, two or four residues).
26 
The observed  
 
cleavage efficiency decreased dramatically and the sequence selectivity was also  
 
affected. Lastly, as a comprehensive study involving derivatization of the methylvalerate  
 
region was reported by Hecht and coworkers
27 
and concluded that not only the  
 
stereochemistry of the methylvalerate but also the length of the moiety served to alter the  
 
DNA cleavage efficiency of the fully incorporated deglycoBLM A6 analogues. These  
 
studies suggest that the linker region and its precise structure serve to facilitate DNA  
 
interaction or cleavage and not just simply connect the two functional domains of  
 
bleomycin. 
 
 The last, non-extensively discussed domain of bleomycin is the disaccharide  
 
moiety, composed of L-gulose and D-mannose, it continues to be a subject of ongoing  
 
study as a consequence of its purported ability to contribute to cellular recognition and  
 
uptake.
28 
Especially important within the disaccharide is a C-3 carbamoyl group  
 
thought to be necessary in cellular recognition as well. In an ongoing study in the Hecht  
 
laboratory it was found that when changing the position of the carbamoyl group (Figure  
 
2.08), altered cellular uptake was observed in fluorescence microscopy studies  
 
(unpublished results).  
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Figure 1.08 Bleomycin disaccharide with an altered carbamoyl position 
 
Displacement of the native C-3 carbamoyl group by molecular oxygen is believed  
 
to be the first step in the formation of an “activated bleomycin”15,29  that is responsible  
 
for mediating the chemistry of DNA strand scission. 
 
 There are two primary pathways associated with bleomycin-mediated DNA  
 
cleavage. One is frank strand scission, which produces base propenals and results directly  
 
in DNA cleavage. The second is via modified nucleotides that result in akali labile  
 
lesions and subsequent cleavage sites in the presence of a base such as alkali or n- 
 
butylamine (Figure 1.09). 
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Figure 1.09 DNA degradation products; (A) frank strand cleavage and (B) oxidative base 
release.
17 
 
 The two sets of DNA products include oligomers terminating with 5ʹ-phosphate  
 
and 3ʹ-phosphoroglycolate moieties,30 and compounds characterized as base propenals.  
 
The second set of DNA products includes free nucleic bases and an alkali-labile  
 
deoxyribose product. Bleomycin was once thought to exert its cytotoxicity exclusively  
 
through DNA degradation;
31-33
 however, there exists evidence of collateral damage of  
 
other cellular components associated with bleomycin activation as well. Bleomycin has  
 
also been shown to attack RNA
34,35
 and even cell walls.
36 
In addition to biochemical  
 
entities, bleomycin (especially in high concentrations) has demonstrated the ability to  
 
mediate chemical transformations of small organic molecules.
16,37,38 
An early study  
 
carried out by Hecht et al.
16
 investigated the chemistry of activated BLM with small  
 
substrates known to be cytochrome P-450 substrates, as the mechanism of action is  
 
reminiscent of that of  cytochrome P-450.
39
 Using Fe(III)•BLM A2 conjugates and  
 
iodosobenzene as an oxygen surrogate, transformations were observed on a variety of  
 
olefins summarized below (Table 1.01).
16
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Table 1.01 Summary of chemical transformations on small molecules by bleomycin A2
16 
 
 The degradation of DNA occurs in a multistep fashion, whose mechanism is not  
entirely understood. It is quite complex and has been the subject of ongoing research  
efforts. The first steps towards the activation of BLM have been previously studied using  
stopped-flow spectroscopy.
40,41 
Researchers postulate that the first step in the process is  
likely to be the addition of O2 to Fe(II)•BLM, followed by displacement of the carbamoyl  
group as a metal binding ligand as shown in Figure 1.04. This transient complex (in vitro)  
has been suggested to yield the bleomycin superoxide species 
∙
O2
-•Fe(III)•BLM. This  
species is then hypothesized to subsequently undergo disproportionation where a  
peroxide-Fe(III)•BLM becomes the active species or “activated BLM” (Figure 1.10).  
This activated species or even the superoxide species intermediate have been suggested to  
have the ability to interact with and degrade DNA when in close proximity (as would be  
facilitated by the bithiazole moiety of BLM).  
 12   
  
 
Figure 1.10 Activated bleomycin formation pathways; reactions with oxygen species and 
reductants form transient ferric peroxide “activated bleomycin”.17 
 Fe(III)•BLM can also give rise to steady-state levels of activated bleomycin by  
reactions with peroxides to form base propenals as DNA cleavage products.
 
 
Additionally, superoxide can contribute to activated bleomycin formation and  
subsequent DNA degradation (Figure 1.11).  
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Figure 1.11 Proposed catalytic cycle of DNA degradation by BLM
42,43
 
 
 As previously described BLM exerts its antitumor effects through the creation of  
 
high reactive metal-oxo-bleomycin complexes. Specifically, Fe
2+
, a redox-active first row  
 
transition element found physiologically, is believed to be the metal ion initially bound to  
 
these complexes. Reaction of the Fe•BLM complex with molecular oxygen results in the  
 
generation of a metal bound peroxide species which subsequently induces DNA strand  
 
scission through abstraction of the C4ʹ hydrogen atom of ribose.  
 
It was the intention of my research to contribute to the construction of a  
 
bleomycin library from which  a structure-activity relationship (SAR) could be derived,  
 
and also could afford more efficacious BLM analogues, possibly for clinical use. 
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Chapter 2 
 
2.01 Introduction 
 
 Although bleomycin is employed clinically in its metal free forms, Blenoxane  
 
(BLM A2, B2) in the United States and BLM A5 in various parts of Asia, the need for  
 
novel and even more efficacious analogues remains a research priority. Previously in the  
 
Hecht laboratory, a 108-member deglycoBLM combinatorial library was synthesized on  
 
a solid support
14,44 
in a parallel fashion (Figure 2.01). This included three bithiazole (C- 
 
terminal DNA binding domain) derivatives, three threonine and three methylvalerate  
 
(linker region) derivatives and four histidine derivatives. The natural pyrimidoblamic  
 
acid was used for all 108 deglycoBLM analogues (Figure 2.04). 
 
While each member of the library was found to be active to some extent in a  
 
concentration-dependent plasmid DNA relaxation assay, two of the analogues exhibited  
 
increased efficiency relative to the parent molecule deglycobleomycin A6. Identification  
 
of novel analogues whose potency surpasses that of the parent natural product continues  
 
to be a research goal. Using a methodology similar to attachment of a solid-support in the  
 
parallel library, it is possible to create a large number of deglycoBLM A6 analogues using  
 
a “split-and-mix” library approach (Figure 2.03). 
 15   
  
 
 
Figure 2.01 Parallel library synthesis of 108 deglycoBLM analogues
 
 
 While each member of the library was found to be active to some extent in a  
 
concentration-dependent plasmid DNA relaxation assay, two of the analogues exhibited  
 
increased efficiency relative to the parent molecule deglycobleomycin A6. Identification  
 
of novel analogues whose potency surpasses that of the parent natural product continues  
 
to be a research goal. Using a methodology similar to attachment of a solid-support in the  
 
parallel library, it is possible to create a vast number of deglycoBLM A6 analogues using  
 
a “split-and-mix” library approach (Figure 2.03). This technique allows the synthesis of  
 
many different analogues simultaneously; however, the need for a visual/fluorescence  
 
assay to identify the active members of such a library continues to be an obstacle for  
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RNA. Previous studies have led to the development of a 16-nt hairpin DNA substrate that  
 
fluoresces in the presence of Fe(II)•BLM (Figure 2.02). 
 
 
Figure 2.02 A 16-nucleotide DNA hairpin containing 4-aminobenzo[g]quinazoline-2-one 
2′-deoxyribose at position 15 was prepared and found to lack significant fluorescence. 
When treated with Fe(II)·BLM, the hairpin was found to undergo oxidative 
transformation selectively at position 15. The pro-fluorescent DNA hairpin was used as a 
substrate for 15 bleomycin congeners.
45 
 
 
 
 
Figure 2.03 Split-and-mix library methodology scheme
 
 
 Whereas the previous parallel library technique provided single analogues to  
 
assay, the “split-and-mix” library technique affords a mixture of many beads, each of  
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which contains numerous molecules of a single analogue. This necessitates a strategy for  
 
identifying individual compounds with the desired properties. Previous strategies include  
 
mass spectrometry techniques. 
 
 There are several synthetic routes available for each of the six amino acids that  
 
comprise (deglyco)BLM, with pyrimidoblamic acid being the most difficult to prepare.  
 
Previous attempts to alter and simplify and change the structure of the heterocycle in  
 
pyrimidoblamic acid have been successful and given rise to three primary types of  
  
synthetic analogues (Figure 2.04).
 
 
 
 
 
Figure 2.04 Natural pyrimidoblamic acid and several simplified pharmacophores 
 
 The total synthesis of pyrimidoblamic acid has been described previously
12,17,18,46 
 
  
 
and its key structurally active elements, (those which play a critical role in O2 activation  
 
in the mechanism of BLM) identified. The synthesis of the complete compound  
 
containing two stereocenters involves very complicated chemical transformations  
 
 18   
  
including stereoselective reactions and preparative TLC or HPLC separation of  
 
enantiomeric or diastereomeric intermediates. Due to the arduous nature of the  
 
diastereomeric selective total synthesis, and the subsequent separations involved,  
 
simplified analogues of PBA (those which retain activity when incorporated into  
 
deglycoBLM) have been identified. This included the omission of a stereocenter (which   
 
incorporation into PBA is synthetically complex) and the associated C-2 acetamido side  
 
chain to create an analogue which behaved similarly when incorporated into BLM.
47
 
 
Further investigations and computational studies based on electron density  
 
profiles, showed certain para-substituted pyridine heterocycles could be substituted in  
 
place of the more complex pyrimidine moiety.
4,6 
This knowledge enabled the creation of  
 
a small library of substituted pyridine and pyrimidine based pyrimidoblamic acid  
 
analogues which were subsequently incorporated into novel deglycoBLM A6 analogues  
 
by solid phase peptide synthesis (Scheme 2.07) and whose activities were analyzed using  
 
a pSP64 supercoiled DNA plasmid relaxation assay (Figures 2.07-2.09). 
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2.02 Results 
 
 Boc-Ser-OH and O-benzylhydroxylamine HCl were coupled using DCC in a 1:1  
 
THF‒H2O solution at pH ~4.5 to afford 2.01 in 60% yield.
48
 Alcohol 2.01 was cyclized  
 
via an intramolecular mitsunobu reaction in THF to give amide 2.02 in good yield  
 
(89%).
13,18 
Amide 2.02 was treated with a saturated methanolic ammonia solution at 0 
o
C  
 
to give amine 2.03 in 81% yield. Amine 2.03 was deprotected using 10% Pd/C in MeOH  
 
under an H2 atmosphere at room temperature over two days and subsequently converted  
 
to its corresponding HCl salt by treatment with HCl gas in a 1:5 MeOH‒Et2O solution at  
 
0 
o
C to give 2.05 in 74% yield over the two steps (Scheme 2.01).
18
 
 
 
Scheme 2.01 Synthesis of the β-aminoalanineamide moiety of PBA (2.04) 
 
Propionamidine HCl was prepared as previously described by Rapaport and co- 
 
workers
49
 by treatment of propionitrile with HCl to form the imidate hydrate  
 
intermediate, and then by treatment with NH3 to give propionamidine HCl 2.06 (Scheme  
 
2.02) in excellent 99% yield. 
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Scheme 2.02 Synthesis of propionamidine HCl (2.06)
49 
 
Pyrimidine 2.07 was prepared by warming a 2:1 mixture of previously prepared  
 
propionamidine HCl, 2.06 and commercially available triethyl 1,3,5-triazine-2,4,6- 
 
tricarboxylate in DMF over a period of three days (Scheme 2.23). Crystallization of the  
 
crude mixture from EtOAc‒hexanes provided pyrimidine 2.07 in 49% yield. Treatment  
 
of 2.07 with NaBH4 (1 eq.) in EtOH at 5 
o
C over a period of 6 days gave the selectively  
 
reduced 2-hydroxymethylpyrimidine (2.08) in modest 25% yield. Alcohol 2.08 was  
 
converted to the corresponding tosylate by treatment with Ts-Cl (1.5 eq.) and K2CO3 (2  
 
eq.) in CH3CN at room temperature for 24 h. Flash column chromatography on silica gel  
 
afforded pure tosylate 2.09 in 78% yield.
13
 Compound 2.09  was coupled with  
 
commercially available N-Boc-ethylenediamine via an SN2 displacement reaction. A  
 
mixture of the tosylate, NaHCO3 (2 eq.), and N-Boc-diamine (4 eq.) in CH3CN was  
 
stirred overnight at 25 
o
C. Filtration, followed by concentration of the solvent in vacuo,  
 
gave the crude coupling product as a colorless oil. Treatment with (Boc)2O (2 eq.) and  
 
Et3N (4 eq.) in CH2Cl2 at room temperature overnight provided the corresponding Boc  
 
protected product 2.10 in nearly quantitative yield (90%) over two steps following the  
 
purification via flash column chromatography on silica gel. Hydrolysis of ester 2.10  
 
afforded the final pyrimidoblamic acid analogue 2.11 using 1 N aq LiOH (2 eq.) in a  
 
mixture of 3:1:1 THF‒MeOH‒H2O. An extensive aqueous workup and subsequent  
 
purification by flash column chromatography on silica gel gave final compound 2.11 as a  
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colorless solid in 60% yield.
12,29
 
 
 
 
Scheme 2.03 Synthesis of 6-amino-2-(((tert-butoxycarbonyl)(2-((tert- 
butoxycarbonyl)amino)ethyl)amino)methyl)-5-methylpyrimidine-4-carboxylic acid 
(2.11) 
 
Tosylate 2.09 was coupled with commercially available cyclic amines a-f  
 
(Scheme 2.24) via an SN2 displacement reaction. A mixture of the tosylate 2.09, NaHCO3  
 
(2 eq.), and the simple N-Boc-protected amine (3 eq.) in CH3CN was stirred overnight at  
 
25 
o
C. Filtration through Celite® followed by concentration of the solvent in vacuo gave  
 
the crude coupling products as a colorless oils. Subsequent treatment with (Boc)2O (2  
 
eq.) and Et3N (4 eq.) in CH2Cl2 at room temperature overnight provided the  
 
corresponding Boc protected products 2.12a-f in yields ranging from 65-98% (over two  
 
steps). Hydrolysis of esters 2.13a-f using LiOH (2 eq.) in a mixture of 3:1:1 THF‒ 
 
MeOH‒H2O gave the corresponding final carboxylic acid products 2.13a-f in moderate to  
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good yields (27-83%) following silica gel flash column chromatography. 
 
 
Scheme 2.04 Synthesis of cyclic pyrimidoblamic acid analogues (2.13a-f) 
 
The esterification of commercially available chelidamic acid monohydrate using  
 
5.5 equivalents of SOCl2 in MeOH at room temperature over a period of three days  
 
afforded diester 2.14 as a colorless solid in 71% yield (Scheme 2.05). Dimethyl  
 
chelidamate 2.14 was then treated with three equivalents of dimethyl sulfate and K2CO3   
 
in DMF at room temperature to give pyridine 2.15 as a colorless solid in 48% yield.
50,51
  
 
Substituted pyridine 2.15 was selectively reduced using NaBH4 in a 6:1 MeOH‒CH2Cl2  
 
solution to give alcohol 2.16 as a colorless solid in 84% yield.
51-53
 Alcohol 2.16 was  
 
treated with ten equivalents of MnO2 in CH2Cl2 at room temperature for 24 h to give  
 
aldehyde 2.17 as a colorless solid in 64% yield.  
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A methanolic solution of 2.05 was passed through a Dowex 1 x 2 ion exchange  
 
column (
-
OH form) to regenerate free base 2.04 in quantitative yields.
18
 A solution of  
 
aldehyde 2.17  in CH3CN was added to a solution of the freshly prepared free amine  
 
2.04 in CH3N in the presence of 4Å powdered molecular sieves at room temperature. The  
 
Schiff base coupling intermediate was treated with 10% Pd/C in MeOH at room  
 
temperature under an H2 atmosphere for 24 hours to generate the corresponding amine,  
 
subsequent protection by treatment with (Boc)2O and Et3N in CH2Cl2 at room  
 
temperature over 24 hours afforded the protected coupling product 2.18 in 80% yield  
 
over the three step sequence (Scheme 2.26). Hydrolysis of ester 2.18 was performed to  
 
obtain the final pyrimidoblamic acid analogue 2.19 using 1 N aq LiOH (2 eq.) in a  
 
mixture of 3:1:1 THF‒MeOH‒H2O. An extensive aqueous workup and subsequent  
 
purification by flash column chromatography on silica gel gave final compound 2.19 as a  
 
colorless solid in 58% yield. 
13,18
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Scheme 2.05 Synthesis of (S)-6-(((3-amino-2-(tert-butoxycarbonylamino)-3-
oxopropyl)(tert-butoxycarbonyl)amino)methyl-4-methoxypicolinic acid (2.19).  
 
 
Chlorination and esterification of commercially available chelidamic acid  
 
monohydrate using 3.2 equivalents of PCl5 in CCl4 and MeOH at reflux followed by  
 
crystallization from MeOH afforded diester 2.20 as colorless needles in 58% yield  
 
(Scheme 2.06).
53,54 
Diester 2.20 was hydrolyzed to the corresponding diacid by treatment  
 
with 1 N aq NaOH to give crude 2.21 in quantitative yields. Crude diacid 2.21  
 
underwent nucleophilic aromatic substitution in 40% (w/w) aq N,N-dimethylamine  
 
solution under pressure to give the crude 4-N,N-dimethylaminopyridine diacid 2.22 in  
 
97% yield. Subsequent treatment with 10 equivalents of SOCl2 in MeOH at reflux  
 
followed by crystallization from acetone provided the corresponding 4-N,N- 
 
dimethylamino diester 2.23 as colorless needles in good yield (78%).
54
 Reduction with  
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1.7 eq. of NaBH4 in a 7:1 CH2Cl2‒MeOH solution afforded the alcohol 2.24 in a modest  
 
46% yield followed by oxidation with ten eq. of MnO2 in warm CH3CN to yield the  
 
corresponding aldehyde 2.25 in 80% yield.  
 
A methanolic solution of 2.05 was passed through a Dowex 1 x 2 ion exchange  
 
column (
-
OH form) to regenerate free base 2.04 in quantitative yields.
18
 A solution of  
 
aldehyde 2.25  in CH3CN was added to a solution of the freshly prepared free amine  
 
2.04 in CH3CN in the presence of 4Å powdered molecular sieves at room temperature.  
 
The Schiff base coupling intermediate was treated with 10% Pd/C in MeOH at room  
 
temperature under an H2 atmosphere for 24 hours to generate the corresponding amine,  
 
then subsequent protection by treatment with (Boc)2O and Et3N in CH2Cl2 at room  
 
temperature over 24 hours afforded the protected coupling product 2.26  in 39% yield  
 
over the three step sequence (Scheme 2.06). Hydrolysis of ester 2.26 was performed to  
 
obtain the final pyrimidoblamic acid analogue 2.27 using 1 N aq LiOH (2 eq.) in a  
 
mixture of 3:1:1 THF‒MeOH‒H2O. An extensive aqueous workup and subsequent  
 
purification by flash column chromatography on silica gel gave final compound 2.27 as a  
 
colorless solid in 57% yield.
13,18
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Scheme 2.06 Synthesis of (S)-6-(((3-amino-2-((tert-butoxycarbonyl)amino)-3-
oxopropyl)(tert-butoxycarbonyl)amino)methyl)-4-(dimethylamino)picolinic acid (2.27) 
 
 Synthesis of the novel deglycoBLM A6 analogues (2.32-2.40) proceeded  
 
efficiently, without complications and followed established protocols in the literature for  
 
solid phase peptide synthesis (Scheme 2.07).
14,44 
Functionalization of the NovaSyn resin  
 
with linker (10 eq.) was done using HBTU and Hunig’s base in DMF and was measured  
 
qualitatively using the Kaiser test. Addition of the Boc-protected spermine was done  
 
similarly using 9 eq. of reagent and was also measured qualitatively using the Kaiser test.  
 
Attachment of the natural Fmoc-bithiazole was accomplished using 3 eq. each, of the  
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Fmoc-protected amino acids, HBTU and Hunig’s base. This process was repeated for  
 
each of the first four amino acids, with the addition of each amino acid measured by  
 
quantitative Fmoc cleavage analysis using 20% piperidine in DMF, and with a yield 
 
>90% for each amino acid addition. For attachment of each of the synthetic novel  
 
pyrimidoblamic acid analogues (Figure 2.07) (2.11, 2.13a-2.13f, 2.19, 2.27) 1.5 eq. of  
 
each were used in addition to 1.5 eq. BOP coupling reagent and 3 eq. of Hunig’s base.  
 
Complete deprotection of the fully synthesized deglycoBLM A6 analogues was done  
 
using triisopropylsilane, (CH3)2S and TFA to remove the Boc and trityl protecting  
 
groups on the resin-bound peptide. Treatment with successive aliquots of a 2% hydrazine  
 
in DMF solution afforded the crude hexapeptide in solution, cleaved from the resin. The  
 
crude deglycoBLM A6 was purified via HPLC, and its mass measured  
 
spectrophotometrically. Each deglycoBLM A6 analogue (2.32-2.40) was analyzed using  
 
a supercoiled DNA plasmid relaxation assay (Figures 2.07-2.09).  
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Scheme 2.07 Representative scheme for solid phase synthesis of deglycoBLM A6 
analogues
14 
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Figure 2.05 Pyrimidoblamic acid analogues incorporated into solid phase synthesis of 
novel deglycoBLM A6 analogues
55
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Figure 2.06 Novel deglycoBLM A6 analogues
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Figure 2.06 Novel deglycoBLM A6 analogues (cont’d)
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Biochemical Results – pSP64 supercoiled DNA plasmid relaxation assay 
 
 The series of novel deglycoBLM A6 analogues (2.32-2.40) were analyzed  
 
for their ability to cleave DNA in a simple supercoiled DNA plasmid relaxation assay  
 
on an agarose gel. Positive (deglycoBLM A5, lanes 2-6) and negative (DNA alone; lane  
 
1, DNA + Fe(II); lane 2) controls were run in addition to the three concentrations (2, 10  
 
and 16 µM) of the analogues. Three forms of DNA are observed on the agarose gel  
 
(I,II,III); Form I, is the supercoiled plasmid DNA, Form II is a single (or minimally  
 
nicked) coiled plasmid DNA and Form III indicates linear duplex DNA (Figures 2.07- 
 
2.09).  
In the first gel (Figure 2.07), analogues 2.32-2.34 all showed DNA relaxation  
 
activity only at the highest (16 µM) concentration. Compound 2.32 displayed minimal  
 
activity at 10 µM whereas compounds 2.33 and 2.34 both showed stronger activity at 10  
 
µM concentration and yielded primarily relaxed coil DNA (Form II). All three  
 
analogues (2.32-2.34) showed similar activity at 10 µM but decreased activity at 16 µM  
 
compared to the control compound, deglycoBLM A5 (Figure 2.07, control; lanes 1-6). As  
 
can be seen for the parent compound deglycoBLM A5 at 16 µM, the entire lane (lane 6)  
 
has been nearly cleared, while none of the analogues displayed such strong activity at 16  
 
µM. 
 
 In the second agarose gel (Figure 2.08) where deglycoBLM A6 analogues 2.35- 
 
2.37 were analyzed, it was found that the three compounds had similar activity at both 10  
 
µM and 16 µM concentrations, and all three appeared inactive at 2 µM. Compound 2.36,  
 
produced relaxed coil DNA (Form II) almost exclusively at 10 and 16 µM 
 
concentrations. Compounds 2.36 and 2.37 showed a more balanced distribution of  
 
relaxed coil (Form II) and linear duplex (Form III) at the higher concentrations (10 µM;  
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lanes 13-14, 16 µM; lanes 17-18). All three compounds showed similar activity to the  
 
control at 10 µM, giving rise to complete depletion of the supercoiled DNA band and  
 
yielding primarily relaxed coil DNA (Form II). At the highest concentration of 16 µM  
 
(lanes 10, 14 and 18), the three compounds displayed decreased activity over the control  
 
(lane 6). 
 
In the third agarose gel (Figure 2.09) where deycloBLM A6 analogues 2.38-2.40  
 
were analyzed, it was found that the three compounds were similarly inactive at 2 µM.  
 
Compound 2.38 and 2.39 showed strong activity at both 10 and 16 µM concentrations  
 
yielding almost exclusively relaxed coil DNA (Form II) with minimal linear duplex DNA  
 
(Form III) seen, with the exception of 2.39 at 16 µM where there appeared a more equal  
 
distribution of degraded DNA. Compound 2.40 displayed different activities at 10 and 16  
 
µM, showing stronger activity than compounds 2.38 and 2.39 at identical concentrations  
 
but decreased activity compared to the control compound deglycoBLM A5 whose lane  
 
was almost completely cleared (lane 6). 
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Figure 2.07 pSP64 DNA plasmid relaxation assay on an agarose gel; deglycoBLM A6; 
analogues 2.32-2.34
 
(I – supercoiled, II – relaxed coil, III – linear duplex) 
Lane 1, 100 ng DNA alone; Lane 2, 16µM Fe(II); Lane 3, 16 µM deglycoBLM A5;  
Lane 4, 2 µM Fe(II)•deglycoBLM A5; Lane 5, 10 µM Fe(II)•deglycoBLM A5; Lane 6, 16 
µM Fe(II)•deglycoBLM A5; Lane 7, 16 µM Fe(II)•deglycoBLM A6 analogue 2.32;  
Lane 8, 2 µM Fe(II)•deglycoBLM A6 analogue 2.32; Lane 9, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.32; Lane 10, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.32; Lane 11, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.33; Lane 12, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.33; Lane 13, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.33; Lane 14, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.33; Lane 15, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.34; Lane 16, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.34; Lane 17, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.34; Lane 18, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.34; 
This experiment was performed by Chenhong Tang. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1      2     3     4      5     6     7     8     9   10    11   12   13   14    15   16   17   18 
III 
II 
II 
) 
I  
) 
DeglycoBLM (µM)                          2.32                  2.33             2.34 
                              2_10_16          2__10__16           2_ 10 _16              _2_10_16 
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Figure 2.08 – pSP64 DNA plasmid relaxation assay on an agarose gel; deglycoBLM A6; 
analogues 2.35-2.37
 
(I – supercoiled, II – relaxed coil, III – linear duplex) 
Lane 1, 100 ng DNA alone; Lane 2, 16µM Fe(II); Lane 3, 16 µM deglycoBLM A5;  
Lane 4, 2 µM Fe(II)•deglycoBLM A5; Lane 5, 10 µM Fe(II)•deglycoBLM A5; Lane 6, 16 
µM Fe(II)•deglycoBLM A5; Lane 7, 16 µM Fe(II)•deglycoBLM A6 analogue 2.35;  
Lane 8, 2 µM Fe(II)•deglycoBLM A6 analogue 2.35; Lane 9, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.35; Lane 10, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.35; Lane 11, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.36; Lane 12, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.36; Lane 13, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.36; Lane 14, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.36; Lane 15, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.37; Lane 16, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.37; Lane 17, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.37; Lane 18, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.37; 
This experiment was performed by Chenhong Tang. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1     2     3    4     5     6    7     8    9   10   11   12   13  14   15   16   17  18 
DeglycoBLM (µM)                  2.35                     2.36             2.37                        
---             2_10_16              2_10_16              2_10 _16              _2_10_16 
  
 
II  
) III  
) I  
) 
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Figure 2.09 – pSP64 DNA plasmid relaxation assay on an agarose gel; deglycoBLM A6; 
analogues 2.38-2.40
 
(I – supercoiled, II – relaxed coil, III – linear duplex) 
Lane 1, 100 ng DNA alone; Lane 2, 16µM Fe(II); Lane 3, 16 µM deglycoBLM A5;  
Lane 4, 2 µM Fe(II)•deglycoBLM A5; Lane 5, 10 µM Fe(II)•deglycoBLM A5; Lane 6, 16 
µM Fe(II)•deglycoBLM A5; Lane 7, 16 µM Fe(II)•deglycoBLM A6 analogue 2.38;  
Lane 8, 2 µM Fe(II)•deglycoBLM A6 analogue 2.38; Lane 9, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.38; Lane 10, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.38; Lane 11, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.39; Lane 12, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.39; Lane 13, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.39; Lane 14, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.39; Lane 15, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.40; Lane 16, 2 µM  
Fe(II)•deglycoBLM A6 analogue 2.40; Lane 17, 10 µM  
Fe(II)•deglycoBLM A6 analogue 2.40; Lane 18, 16 µM  
Fe(II)•deglycoBLM A6 analogue 2.40; 
This experiment was performed by Chenhong Tang. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1     2     3     4    5     6     7    8    9   10   11   12   13  14   15   16   17  18 
II  
) III  
) I  
) 
DeglycoBLM (µM)           2.38                     2.39                       2.40 
                          2_10_16            2_ 10 _16             2   10 _16            _2_  10 _16 
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2.03 Discussion 
 
It was anticipated that structural changes within the N-terminal metal ion binding  
 
domain of BLM would afford analogues having improved biochemical properties. The  
 
pyrimidoblamic acid analogues chosen were structurally similar to the natural  
 
pyrimidoblamic acid or the truncated (but still active) structures (Figure 2.04) whose  
 
fully synthesized deglycoBLM A6 counterparts displayed similar, altered or decreased  
 
activity in the pSP64 supercoiled DNA plasmid relaxation study (Figures 2.07-2.09).  
 
The two pyridine analogues both contained the full native β-aminoalanineamide  
 
side chain while the remaining pyrimidine analogues contained the native core with  
 
various side chains that contained some variation of the simplified ethylene diamine  
 
moiety (partially) responsible for binding the metal co-factor(s).The simplified ethylene  
 
diamine itself is used as the side chain for pyrimidoblamic acid analogue 2.11 and shows  
 
retention of activity in the pSP64 supercoiled DNA plasmid relaxation study (Figure  
 
2.07, lanes 7-10) using the PBA analogue incorporated in the fully synthesized  
 
deglycoBLM A6 analogue 2.32. Further structural changes or even minute additions to  
 
the ethylene diamine side chain (2.13a-2.13f) had a profound effect on the cleavage  
 
efficiency for deglycoBLM A6 analogues 2.35-2.40. The resulting cleavage activity was  
 
initially thought to occur and deviate from the parent compound deglycoBLM A5 because  
 
of the possible inability to bind DNA as efficiently as a result of the structural change in  
 
the pyrimidoblamic acid side chain. However, further consideration led to the idea that  
 
the novel deglycoBLM A6 analogues were unable to chelate a metal co-factors as easily  
 
and thus were less or variably active as a result. Circular dichroism (CD) studies (data not  
 
presented) were done in an attempt to assess which of these hypotheses was more  
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accurate. The studies did show a difference in CD profile from the native Cu(II) chelated  
 
pyrimidoblamic acid (assumed from the interpretation of the difference in spectra  
 
obtained for the analogues 2.35-2.37). The CD studies did not provide enough evidence  
 
to conclude which hypothesis may be playing a stronger role in the difference in cleavage  
 
activities.  
  
 Additional plasmid relaxation assays using different conditions and/or varying the  
 
concentrations of deglycoBLM A6 analogues or its co-factors may reveal more  
 
information about the cleavage activity. Further studies using 3ʹ- or 5ʹ- 32P labeled hairpin  
 
DNA substrates (similarly done in Chapter 3, Figure 3.03) would also lead to more  
 
complete conclusions, including the specific site(s) of cleavage and the preference for  
 
sequence selective cleavage. 
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2.04 Experimental 
  
General Methods: All solvents used were of analytical grade. Anhydrous solvents were  
 
of DriSolv
® 
quality and purchased from VWR. All experiments were run under a dry  
 
nitrogen atmosphere in flame-dried glassware. All other chemicals were purchased from  
 
Aldrich and used without further purification. Flash chromatography was carried out  
 
using Silicycle 200-400 mesh silica gel. Analytical TLC was carried out using 0.25 mm  
 
EM silica gel 60 F250 plates that were visualized by UV irradiation (254 nm). HPLC  
 
separations were performed on an Agilent 1100 series HPLC system using a diode array  
 
detector. The crude products were purified on an Alltech Alltima C18 reversed phase  
 
semi-preparative (250 x 10 mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN  
 
mobile phases. UV-Vis spectrophotometric analysis and quantifications were done using  
 
a Beckman DU Series 500 UV/Vis spectrophotometer equipped with a single cell  
 
module.  
1
H and 
13
C NMR spectra were recorded on a 400 MHz Varian Liquid-State  
 
NMR in chloroform-d. Chemical shifts were reported in parts per million (ppm, δ)  
 
referenced to the residual 
1
H resonance of the solvent (CDCl3, 7.26 ppm). 
13
C spectra  
 
were referenced to the residual 
13
C resonance of the solvent (CDCl3, 77.0 ppm). Splitting  
 
patterns were designated as follows: s, singlet; br, broad; d, doublet; dd, doublet of  
 
doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectra were obtained in  
 
the Arizona State University CLAS High Resolution Mass Spectrometry Laboratory or in  
 
the Michigan State University Mass Spectrometry Facility. 
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N-Boc-L-serine-O-benzylamide (2.01).
18
 To a stirred solution of 6.90 g (33.6 mmol)  
 
Boc-Ser-OH in 70 ml THF was added a solution of 10.7 g (67.3 mmol) of O- 
 
benzylhydroxylamine HCl in 275 mL of H2O at pH ~4.5, at 25 
o
C. The solution was  
 
cooled to 0 
o
C and a solution of 13.9 g (67.3 mmol) of DCC in 205 mL of THF was  
 
added slowly. The reaction mixture was allowed warm to room temperature and was  
 
stirred at 25 
o
C for 3 h. The reaction mixture was concentrated under diminished pressure  
 
and filtered. The precipitate was suspended in 400 mL of hot EtOAc (~60 
o
C) and  
 
filtered. The filtrate was concentrated under diminished pressure to give crude 2.01.  
 
Crystallization from EtOAc gave 2.01 as a colorless solid: yield 6.31 g (60%); mp 129- 
 
130 
o
C, lit.
18
 130-131 
o
C; silica gel TLC Rf 0.43 (1:1 EtOAc‒hexanes); 
1
H NMR (CDCl3)  
 
δ 1.41 (s, 9H), 3.32 (br s, 1H), 3.59 (br s, 1H), 4.02 (m, 2H), 4.89 (s, 2H), 5.58 (m, 1H),  
 
7.36 (m, 5H) and  9.47 (br s, 1H); 
13
C NMR (CDCl3) δ 28.2, 53.1, 62.5, 78.3, 97.5, 128.5,  
 
128.8, 129.2, 134.8, 156.0 and 168.9; mass spectrum (MALDI-TOF) m/z 311.1670 
 
(M+H)
+ 
(C15H23N2O5 requires 311.1609).
 
 
 
 
 
 
(2S)-N-(Benzyloxy)-2-azetidinone (2.02).18 To a stirred solution of 2.83 g (9.12 mmol)  
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of 2.02 and 2.87 g (10.0 mmol) of PPh3 in 60 mL of THF was added 1.57 mL (10.9  
 
mmol) of DEAD at 0 
o
C. The solution was allowed to warm to room temperature and was  
 
stirred at 25 
o
C for 24 h. The solution was concentrated under diminished pressure and  
 
the residue was purified by flash column chromatography on a silica gel column (20 x 4  
 
cm). Elution with 1:1 EtOAc‒hexanes gave 2.02 as a colorless solid: yield 2.37 g (89%);  
 
mp 90-91 
o
C, lit.
18
 91-92 
o
C; silica gel TLC Rf 0.69 (1:1 EtOAc‒hexanes); 
1
H NMR  
 
(CDCl3) δ 1.42 (s, 9H), 3.21 (m, 1H), 3.51 (br s, 1H), 4.53 (br s, 1H), 4.96 (s, 2H), 5.06  
 
(br s, 1H) and 7.39 (m, 5H); 
13
C NMR (CDCl3) δ 28.5, 53.6, 54.7, 78.1, 80.8, 127.6,  
 
128.9, 134.9, 155.2, 163.2 and 168.7; mass spectrum (MALDI-TOF) m/z 293.1544  
 
(M+H)
+ 
(C15H21N2O4 requires 293.1503). 
 
 
 
 
 
(2S)-3-[(Benzyloxy)amino]-2-[(tert-butoxycarbonyl)amino]propanamide (2.03). 
18
 
 
Through a stirred solution of 4.57 g (15.6 mmol) of 2.02 in 70 mL of MeOH was bubbled  
 
NH3 gas for 20 min at 0 
o
C. The solution was stirred at 0 
o
C for 24 h and then  
 
concentrated under diminished pressure. The residue was purified by flash  
 
chromatography on a silica gel column (10 x 4 cm). Elution with 1:1:0.05 EtOAc‒ 
 
hexanes‒MeOH gave 2.03 as a colorless oil: yield 3.89 g (81%); silica gel TLC Rf 0.18  
 
(1:1:0.05 EtOAc‒hexanes‒MeOH); 1H NMR (CDCl3) δ 1.45 (s, 9H), 3.12 (m, 1H), 3.33  
 
(m, 1H), 4.30 (br s, 1H), 4.69 (s, 2H), 5.62 (d, 1H), 5.74 (br s, 1H), 6.56 (br s, 1H) and  
 
7.35 (m, 5H); 
13
C NMR (CDCl3) δ 28.2, 52.3, 52.8, 75.9, 80.1, 127.9, 128.4, 137.3, 155.7  
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and 173.8; mass spectrum (MALDI-TOF) m/z 310.1819 (M+H)
+ 
(C15H24N3O4 requires  
 
310.1769). 
 
 
 
 
  
(2S)-3-Amino-2-[(tert-butoxycarbonyl)amino]propanamide Hydrochloride  
 
(2.05).
18
 To a stirred solution of 3.89 g (12.5 mmol) of 2.02 in 60 mL MeOH was  
 
added a catalytic amount of 10% Pd/C at 25 
o
C. The solution was stirred under a H2  
 
atmosphere at 25 
o
C for 48 h. The reaction mixture was filtered through a Celite® pad,  
 
the pad waswashed with MeOH. The filtrate was concentrated under diminished pressure  
 
to give a colorless oil. The oil was dissolved in 10 mL MeOH and 45 mL of Et2O and to  
 
the solution was added 15 ml of HCl saturated MeOH at 0 
o
C. The reaction mixture was  
 
diluted with 600 mL of Et2O and the resulting suspension was stored at 0 
o
C for 24 h and  
 
then filtered to give 2.05 as a colorless solid: yield 2.22 g (74%); mp 178-180 
o
C, lit.
18
  
 
mp 179-180 
o
C; 
1
H NMR (D2O) δ 1.45 (s, 9H), 3.22 (m, 2H), 3.45 (m, 1H), 4.43 (br s,  
 
1H), 5.13 (br s, 2H) and 6.64 (br s, 2H); 
13
C NMR (D2O) δ 28.3, 43.6, 55.0, 79.9, 155.8  
 
and 174.0; mass spectrum (MALDI-TOF) m/z 240.1188 (M+H)
+ 
(C8H19N3O3Cl requires  
 
240.1117). 
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Propionamidine HCl (2.06).
49 
To a solution of 5.5 mL (77.1 mmol) of propionitrile in  
 
37 mL dry Et2O and 5 mL dry MeOH was bubbled HCl gas for 15 min at 0 
o
C. The  
 
reaction mixture was stirred at 0 
o
C for 48 h. The solution was allowed to warm to room  
 
temperature and was then concentrated under diminished pressure to give a white residue.  
 
The residue was suspended in 50 mL dry EtOH, bubbled with ammonia gas for 20 min  
 
and stirred for at 25 
o
C for 24 h. The reaction mixture was treated with 90 mL of dry Et2O  
 
and stirred at 0 
o
C for 24 h. The resulting precipitate was collected and air dried at 25 
o
C  
 
to give 2.06 as a colorless solid: yield 8.37 g (99%); mp 130 
o
C, lit.
49
 mp 128-130 
o
C; 
1
H  
 
NMR (DMSO) δ 1.15 (t, 3H, J = 7.6 Hz), 2.39 (q, 2H, J = 7.6 Hz) and 9.11 (br s, 3H);  
 
13
C NMR (DMSO) δ 10.1, 29.8 and 168.9; Mass spectrum (MALDI-TOF) m/z 109.0556 
 
(M+H)
+ 
(C3H10N2Cl requires 109.0534). 
 
 
 
 
 
 
Diethyl 6-Amino-2,4-bis(ethoxycarbonyl)-5-methylpyrimidine (2.07).
13,17,18
 A  
 
solution of 2.50 g (8.41 mmol) of triethyl-1,3,5-triazine-2,4,6-tricarboxylate and 1.83 g  
 
(16.8 mmol) of 2.06 in 43 mL of DMF was warmed to 90 
o
C, stirred for 72 h and then  
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concentrated under diminished pressure. The residue was dissolved in 100 mL of warm  
 
(~70 
o
C) EtOAc and filtered. The filtrate was concentrated under diminished pressure and  
 
the residue was crystallized from EtOAc‒hexanes to give 2.07 as an orange solid: yield  
 
1.04 g (49%); mp 148-151 
o
C, lit.
13 
mp 155-156 
o
C; silica gel TLC Rf 0.35 (95:5 CH2Cl2‒ 
 
MeOH); 
1
H NMR (CDCl3) δ 1.42 (t, 3H, J = 7.0 Hz), 1.44 (t, 3H, J = 7.0 Hz), 2.29 (s,  
 
3H), 4.43 (q, 2H, J = 7.0 Hz), 4.48 (q, 2H, J = 7.0 Hz) and 5.93 (br s, 2H); 
13
C NMR δ  
 
12.2, 14.1, 14.1, 62.3, 62.6, 114.8, 153.7, 153.8, 163.7, 164.0 and 165.3; mass spectrum  
 
(MALDI-TOF) m/z 254.1188 (M+H)
+ 
(C11H16N3O4 requires 254.1143). 
 
 
 
 
 
 
Ethyl 6-Amino-2-(hydroxymethyl)-5-methylpyrimidine-4-carboxylate (2.08).
13,18,52  
 
To a stirred solution of 1.85 g (7.31 mmol) of 2.07 in 47 mL EtOH was added 276 mg  
 
(7.31  mmol) of NaBH4 at 0 
o
C. The solution was allowed to warm to 5 
o
C and was  
 
stirred for 150 h. To the solution was added 40 mL of satd aq NaHCO3 and 40 mL of 5%  
 
aq H2O2 and the solution was stirred for an additional 4 h at 5 
o
C and then  
 
concentrated under diminished pressure. The resulting aqueous solution was extracted  
 
with five 40‒mL portions of 4:1 CHCl3‒2-propanol, and the organic extract combined  
 
was concentrated under diminished pressure. The residue was purified by flash  
 
chromatography on a silica gel column (15 x 6 cm). Elution with 95:5 CH2Cl2‒MeOH  
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gave 2.08 as a colorless solid: yield 390 mg (25%); mp 169 
o
C, lit.
13  
mp 169 
o
C; silica gel  
 
TLC Rf 0.27 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.38 (t, 3H, J = 7.0 Hz), 2.14 (s,  
 
3H), 3.31 (br s, 1H), 4.39 (q, 2H, J = 7.0 Hz), 4.48 (s, 2H) and 5.77 (br s, 2H); 
13
C NMR  
 
δ 12.0, 14.4, 63.1, 65.2, 111.28, 154.5, 165.7, 167.0 and 167.7; mass spectrum (MALDI- 
 
TOF) m/z 211.1098 (M+H)
+ 
(C9H14N3O3 requires 212.1037). 
 
 
 
 
 
Ethyl 6-Amino-5-methyl-2-(tosylmethyl)pyrimidine-4-carboxylate (2.09).
13  
To a  
 
stirred solution of 390 mg (1.85 mmol) of 2.08 in 25 mL CH3CN was added 528 mg  
 
(2.77 mmol) of Ts-Cl and 510 mg (3.70 mmol) of K2CO3 at 25 
o
C and the solution was  
 
stirred in the dark for 24 h. The solution was filtered through a Celite® pad and the pad  
 
was washed with CH3CN. The filtrate was concentrated under diminished pressure and  
 
the residue was purified by flash chromatography on a silica gel column (15 x 3 cm).  
 
Elution with 98:2 CH2Cl2‒MeOH gave 2.09 as a colorless solid: yield 527 mg (78%); mp  
 
128 
o
C, lit.
13 
mp 128 
o
C; silica gel TLC Rf 0.55 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3)  
 
δ 1.37 (t, 3H, J = 7.0 Hz), 2.22 (s, 3H), 2.43 (s, 3H), 4.39 (q, 2H, J = 7.0 Hz), 4.96 (s,  
 
2H), 5.77 (br s, 2H), 7.32 (d, 2H, J = 7.1 Hz) and 7.80 (d, 2H, J = 7.1 Hz); 
13
C NMR δ  
 
11.7, 14.1, 21.6, 62.0, 70.8, 111.9, 128.1, 130.0, 131.8, 145.4, 153.0, 159.2, 164.4 and  
 
165.7; mass spectrum (MALDI-TOF) m/z 366.1167 (M+H)
+ 
(C16H20N3O5S requires  
 
366.1125). 
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Ethyl 6-Amino-2-((tert-butoxycarbonyl(2-(tert- 
 
butoxycarbonylamino)ethyl)amino)methyl)-5-methylpyrimidine-4-carboxylate  
 
(2.10).
12,13,18
 To a stirred solution of 410 mg (1.22 mmol) of 2.09 in 6 mL of CH3CN was  
 
added 189 mg (2.44 mmol) of NaHCO3 and 0.71 mL (4.88 mmol) of N-Boc- 
 
ethylenediamine at 25 
o
C. The solution was stirred at 25 
o
C for 24, filtered through a  
 
Celite® pad and the pad was washed with CH3CN. The filtrate was concentrated under  
 
diminished pressure to give a colorless oil. The oil was dissolved in 6 mL CH2Cl2 and to  
 
the solution was added 532 mg (2.44 mmol) of Boc2O and 0.68 mL (4.88 mmol) of Et3N  
 
at 25 
o
C. The solution was stirred at 25 
o
C for 24 h and then concentrated under  
 
diminished pressure. The residue was purified by flash chromatography on a silica gel  
 
column (15 x 3 cm). Elution with 90:10 CH2Cl2‒MeOH gave 2.10 as a colorless foam:  
 
yield 438 mg (79% over 2 steps); silica gel TLC Rf 0.61 (90:10 CH2Cl2‒MeOH); 
1
H  
 
NMR (CDCl3) δ 1.37 (t, 3H, J = 7.0 Hz), 1.41 (s, 9H), 1.43 (s, 9H), 2.16 (m, 2H), 3.20  
 
(br s, 2H), 3.39, (m, 2H), 4.31 (m, 1H), 4.39 (q, 2H, J = 7.0 Hz), 4.91 (br s, 1H) and 5.41  
 
(br s, 2H); 
13
C NMR δ 13.4, 14.1, 28.1, 31.9, 38.3, 51.2, 55.6, 62.0, 70.8, 126.1, 127.5,  
 
113.9, 128.5, 145.5, 157.7, 163.3 and 175.3; mass spectrum (FAB), m/z 454.2674 (M
+
)  
 
(C21H35N5O6 requires 454.2666). 
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6-Amino-2-((tert-butoxycarbonyl(2-(tert- 
 
butoxycarbonylamino)ethyl)amino)methyl)-5-methylpyrimidine-4-carboxylic acid  
 
(2.11).
12,13,17
 To a stirred solution of 151 mg (0.33 mmol) of 2.10 in 3 mL of 3:1:1 THF‒ 
 
MeOH‒H2O was added 0.66 mL (0.66 mmol) of 1 N aq LiOH at 0 
o
C. The solution  
 
was allowed to warm to room temperature and was stirred at 25 
o
C for 3 h and then  
 
concentrated under diminished pressure. The residue was partitioned between H2O and  
 
4:1 CHCl3‒2-propanol (7 mL each). The aqueous phase was extracted with two 7-mL  
 
portions of 4:1 CHCl3‒2-propanol. The aqueous phase was then acidified to pH ~4 with 1  
 
N aq HCl at 0 
o
C and then extracted with five 7-mL portions of 4:1 CHCl3‒2-propanol.  
 
The organic extract combined was concentrated under diminished pressure. The residue  
 
was purified by flash chromatography on a silica gel column (7 x 3 cm). Elution with  
 
88:10:2 CH2Cl2‒MeOH‒acetic acid gave 2.11 as a colorless foam: yield 129 mg (92%);  
 
silica gel TLC Rf 0.58 (90:10 CH2Cl2‒MeOH); 
1
H NMR (D2O) δ 1.34 (s, 9H), 1.38 (s,  
 
9H), 2.05 (s, 3H), 3.06 (m, 2H), 3.31 (m, 2H), 4.26 (s, 2H), 6.90 (br s, 1H) and 7.19 (s,  
 
2H); 
13
C NMR (D2O)  δ 12.3, 28.7, 28.9, 48.2, 51.9, 52.9, 63.1, 79.2, 108.7, 154.2, 155.7,  
 
156.3, 163.8, 164.7 and 167.3; mass spectrum (FAB), m/z 426.2356 (M
+
) (C19H31N5O6  
 
requires 426.2353). 
 
 
 48   
  
 
 
 
Ethyl 6-Amino-2-((tert-butoxycarbonyl((1-(tert- 
 
butoxycarbonylamino)cyclopentyl)methyl)amino)methyl)-5-methylpyrimidine-4- 
 
carboxylate (2.12a). To a stirred solution of 67 mg (0.18 mmol) of 2.09 in 1 mL of  
 
CH3CN was added 31 mg (0.37 mmol) of NaHCO3 and 118 mg (0.55 mmol) of amine a  
 
at 25 
o
C. The solution was stirred at 25 
o
C for 24 h, filtered through a Celite® pad, the  
 
pad was washed with CH3CN and concentrated under diminished pressure. The residue  
 
was dissolved in 1 mL of CH2Cl2 and was added 79 mg (0.36 mmol) of (Boc)2O and 0.10  
 
mL of Et3N at 25 
o
C. The solution was stirred at 25 
o
C for 24 h and then concentrated  
 
under diminished pressure. The residue was purified by flash chromatography on a silica  
 
gel column (12 x 3 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.12a as a colorless oil:  
 
yield 61 mg (67%); silica gel TLC Rf 0.63 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ  
 
1.22 (s, 9H), 1.28 (s, 9H), 1.36 (t, 3H, J = 7.1 Hz), 1.44 (s, 3H), 1.67-1.97 (m, 8H), 2.19  
 
(s, 2H), 4.35 (s, 2H), 4.37 (q, 2H, J = 7.1 Hz), 5.30 (br s, 2H) and 5.71 (br s, 1H).  
13
C  
 
NMR δ 11.6, 14.1, 23.5, 28.1, 28.3, 35.8, 55.4, 55.5, 61.8, 65.2, 79.4, 80.1, 109.6, 153.6,  
 
155.2, 156.8, 163.1, 165.2 and 166.1; mass spectrum (FAB), m/z 507.3063 (M
+
)  
 
(C25H41N5O6 requires 507.3057). 
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Ethyl 6-Amino-2-((tert-butoxycarbonyl((1S,2S)-2-(tert- 
 
butoxycarbonylamino)cyclohexyl)amino)methyl)-5-methylpyrimidine-4-carboxylate  
 
(2.12b). To a stirred solution of 70 mg (0.19 mmol) of 2.09 in 1 mL of CH3CN was  
 
added 32 mg (0.38 mmol) of NaHCO3 and 123 mg (0.57 mmol) of amine b at 25 
o
C. The  
 
solution was stirred at 25 
o
C for 24 h, filtered through a Celite® pad, the pad was washed  
 
with CH3CN and concentrated under diminished pressure. The residue was dissolved in 1  
 
mL of CH2Cl2 and was added 83 mg (0.38 mmol) of (Boc)2O and 0.11 mL of Et3N at 25  
 
o
C. The solution was stirred at 25 
o
C for 24 h and then concentrated under diminished  
 
pressure. The residue was purified by flash chromatography on a silica gel column (12 x  
 
3 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.12b as colorless oil: yield 154 mg  
 
(quant.); silica gel TLC Rf 0.67 (95:5 CH2Cl2‒MeOH); [α]
25
D +46.4
o
 
1
H NMR (CDCl3) δ  
 
1.37 (s, 9H), 1.43 (s, 9H), 1.46 (t, 3H, J = 7.1 Hz), 1.49 (s, 3H), 1.26-2.29 (m, 8H), 2.19  
 
(s, 2H), 3.24 (m, 1H), 4.38 (q, 2H, J = 7.1 Hz) 4.88 (m, 1H), 5.30 (br s, 2H) and 5.71 (br  
 
s, 1H).  
13
C NMR δ 11.5, 14.1, 24.8, 27.3, 28.3, 28.5, 32.9, 55.0, 61.9, 63.4, 64.8, 66.6,  
 
79.1, 85.1, 109.9, 146.7, 156.4, 157.5, 163.7 and 164.1; mass spectrum (FAB), m/z  
 
507.3040 (M
+
) (C25H41N5O6 requires 507.3057). 
 
 
 50   
  
 
 
 
Ethyl 6-Amino-2-((tert-butoxycarbonyl((1R,2R)-2-(tert- 
 
butoxycarbonylamino)cyclohexyl)amino)methyl)-5-methylpyrimidine-4-carboxylate  
 
(2.12c). To a stirred solution of 70 mg (0.19 mmol) of 2.09 in 1 mL of CH3CN was added  
 
32 mg (0.38 mmol) of NaHCO3 and 123 mg (0.57 mmol) of amine c at 25 
o
C. The  
 
solution was stirred for 24 h at 25 
o
C, filtered through a Celite® pad, the pad was washed  
 
with CH3CN and concentrated under diminished pressure. The residue was dissolved in 1  
 
mL of CH2Cl2 and was added 83 mg (0.38 mmol) of (Boc)2O and 0.11 mL of Et3N at 25  
 
o
C. The solution was stirred at 25 
o
C for 24 h and then concentrated under diminished  
 
pressure. The residue was purified by flash chromatography on a silica gel column (12 x  
 
3 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.12c as a colorless oil: yield 100 mg  
 
(quant.); silica gel TLC Rf 0.67 (95:5 CH2Cl2‒MeOH); [α]
25
D -42.7
o
 
1
H NMR (CDCl3) δ  
 
1.37 (s, 9H), 1.43 (s, 9H), 1.46 (t, 3H, J = 7.1 Hz), 1.49 (s, 3H), 1.26-2.29 (m, 8H), 2.19  
 
(s, 2H), 3.24 (m, 1H), 4.38 (q, 2H, J = 7.1 Hz) 4.88 (m, 1H), 5.30 (br s, 2H) and 5.71 (br  
 
s, 1H). 
13
C NMR δ 11.5, 14.1, 24.8, 27.3, 28.3, 28.5, 32.9, 55.0, 61.9, 63.4, 64.8, 66.6,  
 
79.1, 85.1, 109.9, 146.7, 156.4, 157.5, 163.7 and 164.1; mass spectrum (FAB), m/z  
 
507.3040 (M
+
) (C25H41N5O6 requires 507.3057). 
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Ethyl 3-Amino-5-(((tert-butoxycarbonyl)(2-(pyrrolidin-1-yl)ethyl)amino)methyl)-2- 
 
methylbenzoate (2.12d) To a stirred solution of 200 mg (0.49 mmol) of 2.09 and 83 mg  
 
(0.986 mmol) of NaHCO3 in 10 mL of CH3CN was added 233 µL (210 mg, 1.97 mmol)  
 
of amine d at 25 
o
C and the solution was stirred for 12 h. The mixture was filtered  
 
through a pad of Celite®, the pad was washed with CH3CN and concentrated under  
 
diminished pressure. The residue was dissolved in 7 mL of CH2Cl2 and subsequently  
 
treated with 240 mg (0.99 mmol) of Boc2O and 206 µL (150 mg, 1.48 mmol) of Et3N at  
 
25 
o
C and stirred for 12 h. The solution was then concentrated under diminished pressure  
 
and purified by flash chromatography on a silica gel column (10 x 4 cm); elution with 9:1  
 
CH2Cl2‒MeOH gave 2.12d as a colorless foam: yield 127 mg (64%); silica gel TLC Rf  
 
0.53 (9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.31 (s, 9H), 1.38 (t, 3H, J = 7.0 Hz),  
 
3.13 (m, 6H), 2.34 (s, 3H), 3.13 (m, 4H), 3.61 (m, 2H), 3.82 (m, 2H), 4.40 (q, 2H, J = 7.1  
 
Hz), 4.46 (s, 2H) and 6.22 (br s, 2H); 
13
C NMR (CDCl3) δ 13.4, 14.1, 24.5, 28.4, 40.0,  
 
50.1, 56.9, 60.9, 79.8, 118.9, 123.8, 132.2, 146.1, 154.3, 167.5; mass spectrum (FAB),  
 
m/z 405.2619 (M
+
) (C22H35N3O4 requires 405.2628). 
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Ethyl 3-Amino-5-(((tert-butoxycarbonyl)(2-(piperidin-1-yl)ethyl)amino)methyl)-2- 
 
methylbenzoate (2.12e).  To a stirred solution of 200 mg (0.55 mmol) of 2.09 and 91  
 
mg (1.09 mmol) of NaHCO3 in 10 mL of CH3CN was added 233 µL (1.64 mmol) of  
 
amine e at 25 
o
C and the solution was stirred for 12 h. The mixture was filtered through a  
 
pad of Celite®, the pad was washed with CH3CN and concentrated under diminished  
 
pressure. The residue was dissolved in 7 mL of CH2Cl2 and subsequently treated with  
 
240 mg (1.09 mmol) of Boc2O and 300 µL (227 mg, 2.18 mmol) of Et3N at 25 
o
C and  
 
stirred for 12 h. The solution was then concentrated under diminished pressure and  
 
purified by flash chromatography on a silica gel column (10 x 4 cm); elution with 9:1  
 
CH2Cl2‒MeOH gave 2.12e as a colorless foam: yield 134 mg (42%); silica gel TLC Rf  
 
0.54 (9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.31 (s, 9H), 1.38 (t, 3H, J = 7.0 Hz),  
 
3.13 (m, 6H), 2.34 (s, 3H), 3.13 (m, 6H), 3.61 (m, 2H), 3.82 (m, 2H), 4.40 (q, 2H, J = 7.0  
 
Hz), 4.46 (s, 2H) and 6.22 (br s, 2H); 
13
C NMR (CDCl3) δ 13.4, 14.1, 24.5, 25.9, 28.4,  
 
40.0, 50.1, 56.9, 60.9, 79.8, 118.9, 123.8, 132.2, 146.1, 154.3, 167.5; mass spectrum  
 
(FAB), m/z 418.2801 (M
+
) (C23H37N3O4 requires 418.2784). 
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Tert-butyl 4-(3-amino-5-(ethoxycarbonyl)-4-methylbenzyl)piperazine-1-carboxylate  
 
(2.12f) To a stirred solution of 200 mg (0.49 mmol) of 2.09 and 83 mg (0.99 mmol) of  
 
NaHCO3 in 10 mL of CH3CN was added 233 µL (210 mg, 1.97 mmol) of amine f at 25  
 
o
C and the solution was stirred for 12 h. The mixture was filtered through a pad of  
 
Celite®, the pad was washed with CH3CN and concentrated under diminished pressure.  
 
The residue was dissolved in 7 mL of CH2Cl2 and subsequently treated with 240 mg  
 
(0.99 mmol) of Boc2O and 206 µL (150 mg, 1.48 mmol) of Et3N at 25 
o
C and stirred for  
 
12 h. The solution was then reconcentrated under diminished pressure and purified by 
 
flash chromatography on a silica gel column (10 x 4 cm); elution with 9:1 CH2Cl2‒ 
 
MeOH gave 2.12f as a colorless foam: yield 127 mg (64%); silica gel TLC Rf 0.53 (9:1  
 
CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.29 (t, 3H, J = 7.0 Hz), 1.38 (s, 9H), 2.34 (s, 3H),  
 
2.50 (t, 4H, J = 6.5 Hz), 3.20 (t, 4H), J = 6.5 Hz), 3.65 (s, 2H), 4.33 (q, 2H), 6.27 (br s,  
 
2H), 6.69 (s, 1H) and 7.1 (s, 1H); 
13
C NMR (CDCl3) δ 13.4, 14.1, 28.4, 46.2, 54.4, 60.9,  
 
64.5, 79.8, 120.1, 124.2, 132.1, 146.0, 154.7 and 167.8; mass spectrum (FAB), m/z  
 
377.2304 (M
+
) (C20H31N3O4 requires 377.2315). 
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6-Amino-2-((tert-butoxycarbonyl((1-(tert- 
 
butoxycarbonylamino)cyclopentyl)methyl)amino)methyl)-5-methylpyrimidine-4- 
 
carboxylic acid (2.13a). To a stirred solution of 59 mg (0.12 mmol) of 2.12a in 1 mL of  
 
3:1:1 THF‒MeOH‒H2O was added 0.24 mL (0.24 mmol) of 1 N aq LiOH at 0 
o
C. The  
 
solution was allowed to warm to room temperature and was stirred at 25 
o
C for 4 h. The  
 
solution was concentrated under diminished pressure and the residue was partitioned  
 
between H2O and CH2Cl2 (~5 mL each). The aqueous phase was extracted with four 5- 
 
mL portions of CH2Cl2. The organic extract combined was concentrated under  
 
diminished pressure. The residue was purified by flash chromatography on a silica gel  
 
column (12 x 3 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.13a as a colorless foam:  
 
yield 48 mg (83%); silica gel TLC Rf 0.55 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ  
 
1.22 (s, 9H), 1.26 (s, 9H), 1.44 (s, 3H), 1.65-1.95 (m, 8H), 2.20 (s, 2H), 4.35 (s, 2H), 5.30  
 
(br s, 2H), 5.71 (br s, 1H) and 7.10 (br s, 1H).  
13
C NMR δ 11.6, 23.5, 28, 28.3,  
 
35.8, 55.4, 55.5, 65.2, 79.4, 80.1, 109.6, 153.6, 155.2, 156.8, 163.1, 165.2  
 
and 166.1; mass spectrum (FAB), m/z 479.2721 (M
+
) (C23H37N5O6 requires 479.2744). 
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6-Amino-2-((tert-butoxycarbonyl((1S,2S)-2-(tert- 
 
butoxycarbonylamino)cyclohexyl)amino)methyl)-5-methylpyrimidine-4-carboxylic  
 
acid (2.13b). To a stirred solution of 171 mg (0.19 mmol) of 2.12b in 3 mL of 3:1:1  
 
THF‒MeOH‒H2O was added 0.38 mL (0.38 mmol) of 1 N aq LiOH at 0 
o
C. The  
 
solution was allowed to warm to room temperature and was stirred at 25 
o
C for 4 h. The  
 
solution was concentrated under diminished pressure and the residue was partitioned  
 
between H2O and CH2Cl2 (~5 mL each). The aqueous phase was extracted with four 5- 
 
mL portions of CH2Cl2. The organic extract combined was concentrated under  
 
diminished pressure. The residue was purified by flash chromatography on a silica gel  
 
column (12 x 3 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.13b as a colorless foam:  
 
yield 60 mg (66%); silica gel TLC Rf 0.57 (95:5 CH2Cl2‒MeOH); [α]
25
D +62.3
o
 
1
H NMR  
 
(CDCl3) δ 1.37 (s, 9H), 1.43 (s, 9H), 1.49 (s, 3H), 1.26-2.29 (m, 8H), 2.19 (s, 2H), 3.24  
 
(m, 1H), 4.88 (m, 1H), 5.30 (br s, 2H), 5.71 (br s, 1H) and 9.21 (br s, 1H). 
13
C NMR δ  
 
11.5, 24.8, 27.3, 28.3, 28.5, 32.9, 55.0, 63.4, 64.8, 66.6, 79.1, 85.1, 109.9, 146.7, 156.4,  
 
157.5, 163.7 and 164.1; mass spectrum (FAB), m/z 479.2722 (M
+
) (C23H37N5O6 requires  
 
479.2744). 
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6-Amino-2-((tert-butoxycarbonyl((1R,2R)-2-(tert- 
 
butoxycarbonylamino)cyclohexyl)amino)methyl)-5-methylpyrimidine-4-carboxylic  
 
acid (2.13c). To a stirred solution of 95 mg (0.18 mmol) of 2.12c in 3 mL of 3:1:1 THF‒ 
 
MeOH‒H2O was added 0.36 mL (0.36 mmol) of 1 N aq LiOH at 0 
o
C. The solution was  
 
allowed to warm to room temperature and was stirred at 25 
o
C for 4 h. The solution was  
 
concentrated under diminished pressure and the residue was partitioned between H2O and  
 
CH2Cl2 (~5 mL each). The aqueous phase was extracted with four 5-mL portions of  
 
CH2Cl2. The organic extract combined was concentrated under diminished pressure. The  
 
residue was purified by flash chromatography on a silica gel column (12 x 3 cm). Elution  
 
with 95:5 CH2Cl2‒MeOH gave 2.13c as a colorless foam: yield 35 mg (41%); silica gel  
 
TLC Rf 0.57 (95:5 CH2Cl2‒MeOH); [α]
25
D +60.2
o
 
1
H NMR (CDCl3) δ 1.37 (s, 9H), 1.43  
 
(s, 9H), 1.49 (s, 3H), 1.26-2.29 (m, 8H), 2.19 (s, 2H), 3.24 (m, 1H), 4.88 (m, 1H), 5.30  
 
(br s, 2H), 5.71 (br s, 1H) and 9.21 (br s, 1H).  
13
C NMR δ 11.5, 24.8, 27.3, 28.3, 28.5,  
 
32.9, 55.3, 63.4, 64.8, 66.5, 79.0, 85.1, 109.8, 146.6, 156.4, 157.4, 163.2 and 164.2; mass  
 
spectrum (FAB), m/z 479.2722 (M
+
) (C23H37N5O6 requires 479.2744). 
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3-Amino-5-(((tert-butoxycarbonyl)(2-(pyrrolidin-1-yl)ethyl)amino)methyl)-2- 
 
methylbenzoic acid (2.13d). To a stirred solution of 127 mg (0.314 mmol) of 2.12d in 3  
 
mL of 3:1:1 THF‒MeOH‒H2O was added 0.42 mL (0.42 mmol) of 1 N aq LiOH at 0  
 
o
C. The solution was allowed to warm to room temperature and was stirred at 25 
o
C for 3  
 
h. The solution was concentrated under diminished pressure and the residue partitioned  
 
between H2O and 4:1 CHCl3‒2-propanol (7 mL each). The aqueous phase was extracted  
 
with two 7-mL portions of 4:1 CHCl3‒2-propanol. The aqueous phase was then acidified  
 
to pH ~3 with 1 N aq HCl at 0 
o
C and then extracted with five 7-mL portions of 4:1  
 
CHCl3‒2-propanol. The organic extract combined was concentrated under diminished  
 
pressure. The residue was purified by flash chromatography on a silica gel column (6 x 4  
 
cm); elution with 88:10:2 CH2Cl2‒MeOH‒acetic acid gave 2.13d as a colorless foam:  
 
yield 36 mg (30%); silica gel TLC Rf 0.21 (9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.30  
 
(m, 4H), 1.31 (s, 9H), 3.13 (m, 6H), 3.13 (m, 6H), 3.61 (m, 2H), 3.82 (m, 2H), 4.46 (s,  
 
2H), 5.08 (br s, 1H), 6.02 (br s, 1H) and 6.22 (br s, 2H); 
13
C NMR (CDCl3) δ 13.4, 24.5,  
 
25.9, 28.4, 40.0, 79.8, 118.9, 123.8, 132.2, 146.1, 154.3, 167.5; mass spectrum (FAB),  
 
m/z 377.2304 (M
+
) (C20H31N3O4 requires 377.2315). 
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3-Amino-5-(((tert-butoxycarbonyl)(2-(piperidin-1-yl)ethyl)amino)methyl)-2- 
 
methylbenzoic acid (2.13e). To a stirred solution of 134 mg (0.23 mmol) of 2.12e in 3  
 
mL of 3:1:1 THF‒MeOH‒H2O was added 0.46 mL (0.46 mmol) of 1 N aq LiOH at 0  
 
o
C. The solution was allowed to warm to room temperature and was stirred at 25 
o
C for 3  
 
h. The solution was concentrated under diminished pressure and the residue partitioned  
 
between H2O and 4:1 CHCl3‒2-propanol (7 mL each). The aqueous phase was extracted  
 
with two 7-mL portions of 4:1 CHCl3‒2-propanol. The aqueous phase was then acidified  
 
to pH ~3 with 1 N aq HCl at 0 
o
C and then extracted with five 7-mL portions of 4:1  
 
CHCl3-2-propanol. The organic extract combined was concentrated under diminished  
 
pressure. The residue was purified by flash chromatography on a silica gel column (6 x 4  
 
cm); elution with 88:10:2 CH2Cl2‒MeOH‒acetic acid gave 2.13e as a colorless foam:  
 
yield 34 mg (27%); silica gel TLC Rf 0.23 (9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.30  
 
(m, 4H), 1.31 (s, 9H), 2.81-3.13 (m, 6H), 2.34 (s, 3H), 3.13 (m, 6H), 3.61 (m, 2H), 3.82  
 
(m, 2H), 4.46 (s, 2H), 5.08 (br s, 1H) and 6.22 (br s, 2H); 
13
C NMR (CDCl3) δ 13.4, 24.5,  
 
25.9, 28.4, 40.0, 50.1, 56.9, 79.8, 118.9, 123.8, 132.2, 146.1, 154.3, 167.5; mass spectrum  
 
(FAB), m/z 491.2466 (M
+
) (C21H33N3O4 requires 491.2477). 
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3-Amino-5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-2-methylbenzoic acid  
 
(2.13f). To a stirred solution of 127 mg (0.337 mmol) of 2.12f in 3 mL of 3:1:1 THF‒ 
 
MeOH‒H2O was added 0.67 mL (0.67 mmol) of 1 N aq LiOH at 0 
o
C. The solution was  
 
allowed to warm to room temperature and was stirred at 25 
o
C for 3 h. The solution was  
 
concentrated under diminished pressure and the residue partitioned  between H2O and 4:1  
 
CHCl3‒2-propanol (7 mL each). The aqueous phase was extracted with  two 7-mL  
 
portions of 4:1 CHCl3‒2-propanol. The aqueous phase was then acidified to pH ~3  with  
 
1 N aq HCl at 0 
o
C and then extracted with five 7-mL portions of 4:1 CHCl3‒2-propanol.  
 
The organic extract combined was concentrated under diminished pressure. The residue  
 
was purified by flash chromatography on a silica gel column (7 x 4 cm); elution with  
 
88:10:2 CH2Cl2‒MeOH‒acetic acid gave 2.13f as a colorless foam: yield 57 mg (48%);  
 
silica gel TLC Rf 0.16 (9:1 CH2Cl2‒MeOH);
 1
H NMR (CDCl3) δ 1.38 (s, 9H), 2.34 (s,  
 
3H), 2.50 (t, 4H, J = 6.5 Hz), 3.20 (t, 4H, J = 6.5 Hz), 3.65 (s, 2H), 5.03 (br s, 1H) 6.27  
 
(br s, 2H), 6.69 (s, 1H) and 7.1 (s, 1H); 
13
C NMR (CDCl3) δ 13.4, 28.4, 46.2, 54.4, 64.5,  
 
79.8, 120.1, 124.2, 132.1, 146.0, 154.7 and 167.8; mass spectrum (FAB), m/z 349.1994  
 
(M
+
) (C18H27N3O4 requires 349.2002). 
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Dimethyl chelidamate (2.14).
53
 To a stirred solution of 5.0 g (24.9 mmol) of chelidamic  
 
acid monohydrate in 50 mL of MeOH was added 9.9 mL (137 mmol) of SOCl2 at  
 
0 
o
C. The reaction mixture was allowed to warm to room temperature and was stirred  
 
at 25 
o
C for 72 h. The reaction mixture was concentrated under diminished pressure and  
 
the residue was mixed well with 54 ml of an 8% (w/v) aq NH4O2CCH3 solution at 0 
o
C.  
 
The resulting mixture was filtered and subsequent crystallization from MeOH gave 2.14  
 
as colorless crystals: yield 3.71 g (71%); mp 169-170 
o
C, lit.
53 
mp 170-171 
o
C; silica gel  
 
TLC Rf 0.27 (95:5 CH2Cl2-MeOH); 
1
H NMR (CDCl3) δ 3.98 (s, 6H), 7.42 (br s, 1H) and  
 
7.78 (s, 2H). 
13
C NMR (CDCl3) δ 52.0, 92.8, 148.0, 164.9 and 187.2; mass spectrum  
 
(MALDI-TOF), m/z 212.0693 (M+H)
+
  (C9H10NO5 requires 212.0561). 
 
 
 
 
 
Dimethyl 4-methoxypyridine-2,6-dicarboxylate (2.15).
53
 To a stirred solution of 3.71 g  
 
(17.6 mmol) of 2.13 in 30 mL of DMF was added 4.86 g (12.6 mmol) of K2CO3 and  
 
50. mL (53.0 mmol) of (CH3)2SO4 at 25 
o
C. The reaction mixture was stirred at 25 
o
C  
 
for 24 h and then concentrated under diminished pressure to give a colorless solid.  
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The solid was partitioned between CH2Cl2 and H2O (75-mL each) and the aqueous  
 
phase was extracted with four 50-mL portions of CH2Cl2. The combined organic layer  
 
was dried (MgSO4) and concentrated under diminished pressure. Crystallization from  
 
acetone gave 2.15 as colorless needles: yield 1.90 g (48%); mp 126 
o
C, lit.
53
 123-124  
 
o
C; silica gel TLC Rf 0.43 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 3.98 (s, 3H), 4.01  
 
(s, 6H) and 7.82 (s, 2H). 
13
C NMR (CDCl3) δ 53.5, 56.3, 114.3, 149.9, 165.3 and 167.8;  
 
mass spectrum (MALDI-TOF), m/z 226.0762 (M+H)
+
 (C10H12NO5 requires 226.0717). 
 
 
 
 
 
Methyl 6-hydroxymethyl-4-methoxypyridine-2-carboxylate (2.16).
19,53
 To a stirred  
 
solution of 1.90 g (8.44 mmol) of 2.15 in 160 mL of MeOH and 30 mL of CH2Cl2 was  
 
added 543 mg (14.3 mmol) of NaBH4 at 0 
o
C. The solution was allowed to warm  
 
to room temperature and was stirred for 3 h, neutralized to pH ~7 with 1 N HCl and then  
 
concentrated under diminished pressure. The resulting solution was extracted with four  
 
50-mL portions of CH2Cl2. The combined organic layer was dried (MgSO4) and  
 
concentrated under diminished pressure. The residue was purified by flash  
 
chromatography on a silica gel column (20 x 4 cm). Elution with 95:5 CH2Cl2‒MeOH  
 
gave 2.16 as a colorless solid: yield 1.40 g (84%); mp 124-126 
o
C, lit.
19 
mp 127.3-127.5  
 
o
C; silica gel TLC Rf 0.29 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 3.92 (s, 3H), 3.99  
 
(s, 3H), 4.80 (s, 2H), 4.5 (br s, 1H) 7.03 (s, 1H) and 7.58 (s, 1H). 
13
C NMR (CDCl3) δ  
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53.2, 55.9, 64.8, 109.4, 111.0, 148.2, 162.3, 165.5 and 167.3; mass spectrum (MALDI- 
 
TOF), m/z 198.0770 (M+H)
+
  (C9H12NO4 requires 198.0768). 
 
 
 
 
 
Methyl 6-formyl-4-methoxypyridine-2-carboxylate (2.17).
19
 To a stirred solution of  
 
1.40 g (7.10 mmol) of 2.16 in 50 mL of CH2Cl2 was added 6.17 g (71.0 mmol) of  
 
activated MnO2 at 25 
o
C. The mixture was stirred at 25 
o
C for 12 h, then filtered through  
 
a Celite® pad and the pad was washed with CH2Cl2. The filtrate was concentrated under  
 
diminished pressure and the residue was purified by flash chromatography on a silica gel  
 
column (15 x 4 cm). Elution with 95:5 CH2Cl2‒MeOH gave 2.17 as a colorless solid:  
 
yield 883 mg (64%); mp 116-117 
o
C, lit.
19
 116.3-117.1 
o
C; silica gel TLC Rf 0.47 (95:5  
 
CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 3.98 (s, 3H), 4.05 (s, 3H), 7.61 (s, 1H), 7.85 (s, 1H)  
 
and 10.13 (s, 1H); 
13
C NMR (CDCl3) δ 51.3, 55.7, 109.1, 113.4, 149.8, 152.7, 161.2,  
 
165.4 and 191.5; mass spectrum (MALDI-TOF), m/z 196.0540 (M+H)
+
  (C9H10NO4  
 
requires 196.0612). 
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(S)-methyl 6-(((3-amino-2-(tert-butoxycarbonylamino)-3-oxopropyl)(tert- 
 
butoxycarbonyl)amino)methyl)-4-methoxypicolinate (2.18).
  
A solution of 491 mg  
 
(2.05 mmol) of 2.05 in 25 mL MeOH was passed through a Dowex 1 x 2 (
-
OH form)  
 
ion exchange column and concentrated under diminished pressure to regenerate 2.04 as a  
 
colorless oil in quantitative yield. To the oil was added 2.0 g of 4Å powdered molecular  
 
sieves and a solution of 400 mg (2.05 mmol) of 2.17 in 20 mL CH3CN at 25 
o
C. The  
 
mixture was stirred at 25 
o
C for 24 h, filtered through a Celite® pad and the pad was  
 
washed with CH3CN. The filtrate was concentrated under diminished pressure and the  
 
residue was dissolved in 30 mL MeOH, treated with a catalytic amount of 10% Pd/C and  
 
stirred under a H2 atmosphere at 25 
o
C for 24 h. The mixture was filtered through a  
 
Celite® pad, the pad was washed with MeOH and concentrated under diminished  
 
pressure. The residue was dissolved in 25 mL of CH2Cl2 and to the solution was added  
 
895 mg (4.10 mmol) of (Boc)2O and and 1.14 mL (8.2 mmol) Et3N at 25 
o
C. The solution  
 
was stirred for 24 h at 25 
o
C and then concentrated under diminished pressure to give  
 
crude 2.18 as a yellow oil. The oil was purified by flash chromatography on a silica gel  
 
column (25 x 4 cm). Elution with 9:1 CH2Cl2‒MeOH gave 2.18 as a colorless foam: yield  
 
793 mg (80%); silica gel Rf 0.50 (9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.39 (s, 9H),  
 
1.40 (s, 9H), 3.47 (m, 1H), 3.89 (s, 3H), 3.91 (s, 3H), 3.9-4.0 (m, 2H), 4.2-4.8 (m, 2H),  
 
5.61 (s, 1H), 6.85 (d, 1H), 7.51 (d, 1H), 7.93 (br s, 1H) and 8.47 (br s, 1H). 28.4, 28.6,  
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50.7, 51.2, 53.5, 54.4, 56.6, 80.4, 81.8, 111.2, 111.4, 149.8, 157.3, 162.1, 162.7, 166.7,  
 
168.8 and 175.4; mass spectrum (FAB), m/z 483.2477 (M+H)
+
  (C22H35N4O8 requires  
 
483.2457).  
 
 
 
 
 
(S)-6-(((3-amino-2-(tert-butoxycarbonylamino)-3-oxopropyl)(tert- 
 
butoxycarbonyl)amino)methyl)-4-methoxypicolinic acid (2.19).
  
To a stirred solution  
 
of 161 mg (0.33 mmol) of 2.18 in 5.6 mL of 3:1:1 THF‒MeOH‒H2O was added 0.66 mL  
 
of 1 N aq LiOH at 0 
o
C. The solution was allowed to warm to room temperature and was  
 
stirred at 25 
o
C for 3 h. The solution was acidified to pH ~4.0 with 1 N aq HCl and  
 
concentrated under diminished pressure. The residue was dissolved in 10 mL H2O and  
 
extracted with four 20-mL portions of CH2Cl2. The organic layers were combined and  
 
concentrated under diminished pressure. The residue was purified by flash  
 
chromatography on a silica gel column (15 x 2 cm). Elution with 9:1 CH2Cl2‒MeOH  
 
gave 2.19 as a colorless foam: yield 90 mg (58%); silica gel Rf 0.50 (9:1 CH2Cl2‒MeOH);  
 
1
H NMR (D2O) δ 1.41 (s, 9H), 1.40 (s, 9H), 3.39 (t, 1H), 3.91 (s, 3H), 3.9-4.2 (m, 2H),  
 
4.4-5.0 (m, 2H), 5.85 (d, 1H), 6.87 (d, 1H), 7.58 (d, 1H), 7.93 (br s, 1H) and 8.47 (br s,  
 
1H) 9.23 (br s, 1H); 
13
C NMR (CDCl3) δ 27.7, 27.9, 49.6, 53.7, 53.9, 55.6, 79.8, 80.5,  
 
110.2, 110.5, 148.9, 156.5, 160.8, 161.5, 165.4, 167.7 and 174.4; mass spectrum  
 
(MALDI-TOF), m/z 470.2357 (M+H)
+
 (C21H33N4O8 requires 470.2378). 
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Dimethyl 4-chloropyridine-2,6-dicarboxylate (2.20).
54
 To a stirred solution of 10.0 g  
 
(59.7 mmol) of chelidamic acid monohydrate in 100 mL CCl4 was added 33.1 g (159  
 
mmol) of PCl5 at 25 
o
C. The solution was heated at reflux at 85 
o
C and stirred for 15 h.  
 
The solution was allowed to cool to 40 
o
C and 30 mL of MeOH was slowly added. The  
 
solution was heated to reflux at 70
 o
C and stirred for 3 h. The mixture was cooled to 0 
o
C  
 
and filtered. Crystallization from MeOH gave 2.20 as colorless needles: yield 6.63 g  
 
(58%); mp 142 
o
C, lit.
54
 141-142 
o
C; silica gel TLC Rf 0.67 (95:5 CH2Cl2‒MeOH); 
1
H  
 
NMR (CDCl3) δ 3.97 (s, 3H) and 8.24 (s, 2H); 
13
C NMR (CDCl3) δ 55.7, 128.5, 147.0,  
 
149.6 and 164.2; mass spectrum (MALDI-TOF), m/z 230.0236 (M+H)
+
  (C9H9NO4Cl  
 
requires 230.0222). 
 
 
 
 
4-Methoxypyridine-2,6-dicarboxylic acid (2.21).
19,53,54
 A suspension of 6.63 g (28.9  
 
mmol) of 2.20 in 72 mL (72.0 mmol) of 1 N aq NaOH was heated to 80 
o
C and  
 
stirred for 4 h. The solution was cooled to 0 
o
C and acidified to pH ~4 with 1 N aq HCl.  
 
The precipitate was collected and dried to give 2.21 as a colorless solid: yield 6.80 g  
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(quant.); mp 266 
o
C, lit.
52
 265-267 
o
C; mass spectrum (MALDI-TOF), m/z 201.9919  
 
(M+H)
+
  (C7H4NO4Cl requires 201.9909). 
 
 
 
 
 
4-Dimethylaminopyridine-2,6-carboxylic acid (2.22).
54
 A suspension of 3.83 g  
 
(19.0 mmol) of 2.21 in 135 mL of 40% (w/w) aq N,N-dimethylamine solution was  
 
heated in a sealed vessel to 135 
o
C and stirred for 24 h. The solution was cooled to 0
 o
C  
 
and acidified to pH ~3 with conc. aq H2SO4. The precipitate was collected and dried to  
 
give 2.22 as a colorless solid: yield 3.72 g (97%); mp 262 
o
C, lit.
54 
mp 260-262 
o
C; mass  
 
spectrum (MALDI-TOF), m/z 211.0779 (M+H)
+
  (C9H11N2O4 requires 211.0721). 
 
 
 
 
 
Dimethyl 4-dimethylaminepyridine-2,6-dicarboxylate (2.23).
54 
To a stirred  
 
suspension of 2.40 g (11.4 mmol) of 2.22 in 90 mL of MeOH was added 8.3 mL (114  
 
mmol) of SOCl2 at 0 
o
C. The solution was heated to reflux at 75 
o
C and stirred for 5 h and  
 
then concentrated under diminished pressure. The residue was mixed well with 90 mL of  
 
8% (w/w) aq solution of NH4O2CCH3 at 0 
o
C and the precipitate was collected and  
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dried. The crude material was crystallized from acetone to give 2.23 as colorless  
 
needles: yield 2.11 g (78%); mp 168 
o
C, lit.
54
 168-170 
o
C; silica gel TLC Rf 0.51 (95:5  
 
CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 3.13 (s, 6H), 3.98 (s, 6H) and 7.51 (s, 2H); 
13
C  
 
(CDCl3) δ 39.4, 53.0, 110.2, 148.5, 155.7 and 166.2; mass spectrum (MALDI-TOF), m/z  
 
239.1079 (M+H)
+
 (C11H15N2O4 requires 239.1034). 
 
 
 
 
 
Methyl 4-((Dimethyl)amino)-6-(hydroxymethyl)picolinate (2.24).
13,18,54
 To a stirred  
 
solution of 1.00 g (4.20 mmol) of 2.23 in 16 mL of CH2Cl2 and 78 mL of MeOH was  
 
added 270 mg (7.14 mmol) of NaBH4 at 0 
o
C. The solution was allowed to warm to room  
 
temperature and was stirred at 25 
o
C for 4 h. The reaction mixture was then acidified to  
 
pH 3 using 1 N aq HCl and then concentrated under diminished pressure. The resulting  
 
solution was extracted with four 50-mL portions of CH2Cl2. The combined organic layer  
 
was dried (MgSO4) and concentrated under diminished pressure. The residue was  
 
purified by flash chromatography on a silica gel column (20 x 4 cm). Elution with 95:5  
 
CH2Cl2‒MeOH gave 2.24 as a colorless solid: yield 665 mg (75%); mp 79-81 
o
C, lit.
54  
 
mp 81-82 
o
C; silica gel TLC Rf 0.28 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 3.01 (s,  
 
6 H), 3.89 (s, 3H), 4.32 (s, 2H), 5.23 (br s, 1H), 7.03 (s, 1H) and 7.58 (s, 1H); 
13
C NMR  
 
(CDCl3) δ 41.3, 52.7, 55.4, 64.6, 108.9, 110.1, 148.2, 165.2 and 167.1; mass spectrum  
 
(MALDI-TOF), m/z 211.1112 (M+H)
+
 (C10H15N2O3 requires 211.1084). 
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Methyl 4-((Dimethyl)amino)-6-formylpicolinate (2.25).
 13,18,54
  To a stirred solution of  
 
213 mg (1.01 mmol) of 2.24 in 15 mL of CH3CN was added 878 mg (10.10 mmol) of  
 
MnO2 at 25 
o
C. The reaction mixture was heated to 45 
o
C for 24 h, allowed to cool to  
 
room temperature, then filtered through a pad of Celite
® 
and the pad was washed with  
 
CH3CN. The filtrate was concentrated under diminished pressure and the residue was  
 
purified by flash column chromatography on a silica gel column (10 x 3 cm); elution with  
 
95:5 CH2Cl2‒MeOH gave 2.25 as a colorless solid: yield 56 mg (26%); mp 116.0-117.0  
 
o
C, lit.
54
 117.0-117.5 
o
C; silica gel TLC Rf 0.43 (95:5 CH2Cl2‒MeOH); 
1
H NMR (CDCl3)  
 
δ 2.88 (s, 6H), 3.79 (s, 3H), 6.98 (s, 1H), 7.24 (s, 1H) and 9.81 (s, 1H); 13C (CDCl3) δ  
 
38.9, 52.5, 105.3, 110.7, 148.1, 152.4, 154.8, 165.3 and 193.3; mass spectrum (MALDI- 
 
TOF), m/z 209.0964 (M+H)
+
 (C10H13N2O3 requires 209.0928). 
 
 
 
 
 
(S)-Methyl 6-(((3-Amino-2-(tert-butoxycarbonylamino)-3-oxopropyl)(tert- 
 
butoxycarbonyl)amino)methyl)-4-dimethylaminopicolinate (2.26).
  
A solution of  
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100 mg (0.42 mmol) of 2.05 in 10 mL MeOH was passed through a Dowex 1 x 2 (
-
OH  
 
form) ion exchange column and concentrated under diminished pressure to regenerate  
 
2.04 as a colorless oil in quantitative yield. To the oil was added 0.42 g of 4Å powdered  
 
molecular sieves and a solution of 87 mg (0.42 mmol) of 2.25 in 5 mL CH3CN at 25 
o
C.  
 
The mixture was stirred at 25 
o
C for 24 h, filtered through a Celite® pad and washed with  
 
CH3CN. The filtrate was concentrated under diminished pressure and the residue was  
 
dissolved in 20 mL MeOH, treated with a catalytic amount of 10% Pd/C and stirred under  
 
a H2 atmosphere at 25 
o
C for 24 h. The mixture was filtered through a Celite® pad, the  
 
pad was washed with MeOH and then concentrated under diminished pressure. The  
 
residue was dissolved in 15 mL of CH2Cl2 and to the solution was added 183 mg (0.84  
 
mmol) of (Boc)2O and and 0.23 mL (1.68 mmol) of Et3N at 25 
o
C. The solution was  
 
stirred at 25 
o
C for 24 h and then concentrated under diminished pressure. The residue  
 
was purified by flash chromatography on a silica gel column (16 x 2 cm). Elution with  
 
95:5 CH2Cl2‒MeOH gave 2.26 as a colorless foam: yield 82 mg (39%); silica gel Rf 0.53  
 
(9:1 CH2Cl2‒MeOH); 
1
H NMR (CDCl3) δ 1.29 (s,18H), 2.94 (s, 6H), 3.41 (m, 2H), 3.71  
 
(m, 3H), 4.2-4.9 (m, 3H), 5.99 (s, 1H), 6.36 (s, 1H), 6.36 (s, 1H), 7.17 (s, 1H) and 8.59 (s  
 
1H); 
13
C NMR (CDCl3) δ 27.9, 28.0, 39.0, 51.1, 52.2, 52.4, 53.7, 79.0, 80.2, 106.4, 107.4,  
 
146.9, 155.2, 155.6, 158.5, 158.9, 166.0 and 172.6; mass spectrum (FAB), m/z 497.2880  
 
(M+H)
+
, (C23H38N5O7 requires 497.2851). 
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(S)-6-(((3-Amino-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)(tert- 
 
butoxycarbonyl)amino)methyl)-4-(dimethylamino)picolinic acid (2.27).
  
To a  
 
stirred solution of 145 mg (0.36 mmol) of 2.26 in 8 mL of 3:1:1 THF‒MeOH‒H2O was  
 
added 0.7 mL of 1 N aq LiOH at 0 
o
C. The solution was allowed to warm to room  
 
temperature and was stirred at 25 
o
C for 3 h. The solution was acidified to pH ~4.0 with  
 
1 N aq HCl and concentrated under diminished pressure. The residue was dissolved in  
 
10 mL H2O and extracted with four 20-mL portions of CH2Cl2. The organic layers were  
 
combined and concentrated under diminished pressure. The residue was purified by flash  
 
chromatography on a silica gel column (15 x 2 cm). Elution with 9:1 CH2Cl2‒MeOH  
 
gave 2.27 as a colorless foam: yield 80 mg (53%); silica gel Rf 0.48 (9:1 CH2Cl2‒MeOH);  
 
1
H NMR (D2O) δ 1.41 (s, 9H), 1.40 (s, 9H), 2.96 (s, 6H), 3.14 (t, 1H), 3.51-3.90 (m, 4H),  
 
5.64 (br s, 1H), 6.87 (d, 1H), 7.58 (d, 1H), 7.93 (br s, 1H), 8.47 (br s, 1H) and 9.01 (br s,  
 
1H); mass spectrum (FAB), m/z 483.2704 (M+H)
+
, (C22H36N5O7 requires 483.2695). 
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Incorporation of pyrimidoblamic acid analogues (2.11, 2.13a-2.13f, 2.19, 2.27) 
Figure 2.04, Schemes 2.01-2.06) into novel deglycoBLM A6 analogues (2.32-2.40, 
Figure 2.06) 
 
 
Procedure for the functionalization of resin (2.27).
14 
100 mg of resin (0.048 mmol) 
(NOVASYNTG amino Resin, 0.048 mmol/g loading capcaity) was added in a solid phase 
test tube. The beads were rinsed with DMF (3 x 4 mL), and DCM (3 x 4 mL) 10 min each 
and then washed with DMF (3 x 4 mL). A solution containing 42.5 mg (0.144 mmol) of 
DDE-linker, 54 mg (0.144 mmol) of HBTU, and 50 µL (0.288 mmol) of DIPEA in 1.5 
mL of DMF was added to the test tube containing beads and stirred overnight. The resin 
was filtered and washed with (3 x 3 mL) DMF, (3 x 3 mL) DCM, (3 x 3 mL) MeOH. The 
resulting resin was qualitatively tested by the Kaiser Test. The resin was dried under 
vacuum overnight.  
 
General Procedure for the Attachment of Bithiazole to the Solid Support (2.28).
14
 To 
a suspension containing 100 mg (0.48 mmol/g) of NovaSyn TentaGel amino 
functionalized resin was added a solution containing 170 mg (0.439 mmol) of Boc-
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protected permine
26
 and 96 uL (71 mg, 0.548 mmol) Hunig’s base in 4 mL DMF. After 
24 h, the resin was filtered, and washed for 30 s each with three 5-mL potions of DMF, 
three 5-mL portions of CH2Cl2, and three 5-mL portions of MeOH and then three 5-mL 
portions of DMF. A solution containing 69 mg (0.144 mmol) fmoc-bithiazole, 54 mg 
(0.144 mmol) of HBTU, and 50 uL of Hunig’s base in 4 mL DMF was added. After 30 
min, the resin was filtered, washed for 30 s each with three 5-mL potions of DMF, three 
5-mL portions of CH2Cl2, and three 5-mL portions of MeOH. The resulting resin was 
dried under diminished pressure over KOH pellets. Quantatative Fmoc cleavage analysis 
indicated a loading of 0.18 mm/g (60% over three steps). 
 
General Procedure for the Attachement of Threonine to the Resin-Bound Dipeptide 
(2.29).
14
 To a suspension containing 100 mg bithiazole-functionalized resin was added 
sequentially for 5 min each, three 4-mL solutions containing 20% piperidine in DMF. 
The resulting resin was washed for 30 s each with three 10-mL portions of DMF, three 
10-mL portions of CH2Cl2, and then three 10-mL portions of DMF. A solution containing 
49 mg (0.144 mmol) of Fmoc-threonine, 54 mg (0.144 mmol) of HBTU, 19 mg (0.144 
mmol) of HOBt, and 28 uL (37 mg, 0.288 mmol) of Hunig’s base in 4 mL of DMF was 
added. After 30 min the resin was filtered and washed with three 5-mL portions of DMF, 
three 5-mL portions of CH2Cl2, and again with three 5-mL portions of MeOH. The 
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resulting resin was dried under diminished pressure over KOH pellets. Quantitative Fmoc 
cleavage analysis indicated a loading of 0.18 mmol/g (93%). 
 
General Procedure for the Attachment of Methylvalerate to the Resin-Bound 
Tripeptide (2.30).
14
 To a suspension containing 100 mg of the derivatized resin was 
added successively three 1.0-mL solutions containing 20% piperidine in DMF. The 
resulting resin was washed for 30 s each with three 5-mL portions of DMF, three 5-mL 
portions of CH2Cl2, and then three 5-mL portions of DMF. A solution containing 53 mg 
(0.144 mmol) of Fmoc-methylvalerate, 55 mg (0.144 mmol) of HBTU, 19 mg (0.144 
mmol) of HOBt and 27 uL (37 mg, 0.288 mmol) of Hunig’s base in 1 mL DMF was 
added. After 30 min, the resin was filtered and washed with three 5-mL portions of DMF, 
three 5-mL portions of CH2Cl2, and again with three 5-mL portions of MeOH. The 
resulting resin was dried under diminished pressure over KOH pellets. Quantitative Fmoc 
cleavage analysis indicated a loading of 0.17 mmol/g (90%). 
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General Procedure for the Attachment of Histidine to the Resin-Bound 
Tetrapeptide (2.31).
14
 To a suspension containing 60 mg of the derivatized resin was 
added successively three 1.0-mL solutions containing 20% piperidine in DMF. The 
resulting resin was washed for 30 s each with three 5-mL portions of DMF, three 5-mL 
portions of CH2Cl2, and then three 5-mL portions of DMF. A solution containing 89 mg 
(0.144) of Fmoc-trityl-histidine, 55 mg (0.144 mmol) of HATU, 20 mg (0.144 mmol) of 
HOAt, and 27 uL (37 mg, 0.144 mmol) of Hunig’s base in 1-mL of DMF was added. 
After 30 min, the resin was filtered and washed for 30 s each with three 5-mL portions of 
DMF, three 5-mL portions of CH2Cl2, and then three 5-mL portions of MeOH. The 
resulting resin was dried under diminished pressure over KOH pellets. Quantitative Fmoc 
cleavage analysis indicated a loading of 0.16 mmol/g (90%). 
 
General Procedure for the Synthesis of Deglycobleomycin A6 (Analogues) (2.32-
3.40).
14
 To a suspension containing 40 mg of the pentapeptide derivatized resin was 
added successively, three 1.0-mL solutions containing 20% piperidine in DMF. The 
resulting resin was washed for 30 s each with three 5-mL portions of DMF, three 5-mL 
portions of CH2Cl2, and then three 5-mL portions of DMF. The resin was then added to a 
10 mL round bottom flask containing 1-mL of DMF and cooled to 0 
o
C for 10 min. A 
mixture containing 16-20 mg (0.072. mmol) of a Boc-pyrimidoblamic acid analogue 
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2.11, 2.13a-2.13f, 2.19, 2.27 and 27 mg (0.072 mmol) of BOP was added to the resin 
with an additional 1-mL of DMF. The reaction mixture was cooled for an additional 10 
min followed by the addition of 13 µL (27 mg, 0.144 mmol) of Hunig’s base. After 16 h, 
the resin was filtered and washed for 30 s each with three 5-mL portions of DMF, three 
5-mL portions of CH2Cl2, and then three 5-mL portions of MeOH. The resulting resin 
was dried under diminished pressure over KOH pellets. 
 
General Procedure for the Cleavage of Deglycobleomycin A6 (Analogues) from the 
Resin.
14
 To a suspension containing 30 mg of resin-bound fully protected 
deglycobleomycin A6 (analogue) was added a solution containing 200 µL of 
triisopropylsilane and 200 µL of (CH3)2S. After 10 min, 4 mL of TFA was added to the 
suspension. After 4 h, the resin was filtered and washed with five 3-mL portions of 
CH2Cl2, and five 3-mL portions of DMF. The resulting resin was treated successively 
with four 1-mL portions of a 2% hydrazine in DMF solution over 40 min. The eluate was 
collected and concentrated under diminished pressure at <30 
o
C. The resulting oil was 
dissolved in 5-mL of a 0.1% aq TFA solution, frozen and lyophilized to give the crude 
residue. 
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Fully Synthesized DeglycoBLM A6 Analogues Altered at the Pyrimidoblamic aAcid 
Moiety (Figure 2.06) 
 
DelcycoBLM A6 Analogue 2.32. The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.32. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.1 min and were collected, frozen, and lyophilized to give 2.32 as a 
colorless solid: yield 2.26 mg (88% over two steps); mass spectrum (TOF ESI), m/z 
1013.5170 (M
+
) (C44H71N17O7S2 requires 1013.5164). 
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DelcycoBLM A6 Analogue 2.33. The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.33. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 13.9 min and were collected, frozen, and lyophilized to give 2.33 as a 
colorless solid: yield 1.28 mg (45% over two steps); mass spectrum (TOF ESI), m/z 
10056.5130 (M
+
) (C46H72N16O9S2 requires 1056.5110). 
 
DelcycoBLM A6 Analogue 2.34. The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.34. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 13.8 min and were collected, frozen, and lyophilized to give 2.34 as a 
colorless solid: yield 1.37 mg (55% over two steps); mass spectrum (TOF ESI), m/z 
1069.5434 (M
+
) (C46H72N16O9S2 requires 1069.5426). 
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DelcycoBLM A6 Analogue 2.35. The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.35. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.35 as a 
colorless solid: yield 1.78 mg (65% over two steps); mass spectrum (TOF ESI), m/z 
1067.5650 (M
+
) (C48H77N17O7S2 requires 1067.5633). 
 
 
DelcycoBLM A6 Analogue 2.36. The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
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2.36. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.36 as a 
colorless solid: yield 1.33 mg (50% over two steps); mass spectrum (TOF ESI), m/z 
1067.5651  (M
+
) (C48H77N17O7S2 requires 1067.5633). 
 
 
DelcycoBLM A6 Analogue 2.37. The crude residue was dissolved in 0.1% aq. TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.37. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.37 as a 
colorless solid: yield 1.55 mg (61% over two steps); mass spectrum (TOF ESI), m/z 
1067.5654 (M
+
) (C48H77N17O7S2 requires 1067.5633). 
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DelcycoBLM A6 Analogue 2.38.
 
The crude residue was dissolved in 0.1% aq. TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.38. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.38 as a 
colorless solid: yield 1.78 mg (66% over two steps); mass spectrum (TOF ESI), m/z 
1067.5643 (M
+
) (C48H77N17O7S2 requires 1067.5633). 
 
 
DelcycoBLM A6 Analogue 2.39.
 
The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.39. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
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semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.39 as a 
colorless solid: yield 1.69 mg (69% over two steps); mass spectrum (TOF ESI), m/z 
1081.5788  (M
+
) (C48H77N17O7S2 requires 1081.5790). 
 
DelcycoBLM A6 Analogue 2.40.
 
The crude residue was dissolved in 0.1% aq TFA to 
give a solution containing 1 mg/mL of the fully deprotected deglycoBLM A6 analogue  
2.40. The solution was purified on an All-Tech C18 (10 x 250 mm, 5 µm) reversed phase 
semi-preparative HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 50:50 0.1% aq TFA‒CH3CN) 
over a period of 30 min at a flow rate of 3.5 mL/min. Fractions containing the desired 
product eluted at 14.2 min and were collected, frozen, and lyophilized to give 2.40 as a 
colorless solid: yield 1.88 mg (75% over two steps); mass spectrum (TOF ESI), m/z 
1039.5328 (M
+
) (C46H73N17O7S2 requires 1039.5320) 
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Chapter 3 
 
3.01 Introduction 
 
 Surface plasmon resonance (SPR) biosensor techniques can directly provide  
 
essential kinetic and even mechanistic information for the study and characterization of  
 
small molecule‒nucleic acid interactions. The method is label free and can monitor the  
 
interactions in real time. Both dynamic and steady-state information can be obtained for a  
 
variety of rates and binding affinities.
56 
SPR biosensor techniques are the fundamental  
 
principle of many “lab-on-a-chip” sensors and work by measuring the oscillations or  
 
difference in collective oscillations of free electron gas density, or “plasmons”. A  
 
plasmon is a quantum of plasma oscillation analogous to the way in which photons or  
 
phonons are quantizations of electromagnetic and mechanical vibrations. However the  
 
photon is an elementary particle, whereas the plasmon remains a quasiparticle. When the  
 
affinity of two ligands must be determined by surface plasmon resonance (i.e. small  
 
molecule‒nucleic acid interactions), the binding constant must be measured and can be  
 
found using the dynamical SPR model and the standard equation (Equation 3.11). 
 
 
 
 
Equation 3.01 Binding constant determination by ligand interaction 
 
 In a biosensor evaluation of a ligand (L) and a nucleic acid binding site (D) the  
 
components bind to give a complex (LD), where either D or L must be  
 
immobilized/functionalized on the surface of a chip.
56
 This is easily achieved with  
 
nucleic acids which can be biotinylated at either the 5ʹ or 3ʹ terminus, used in conjunction  
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with a chip surface that has been coated with streptavidin (Figure 3.01). It has also been  
 
shown to be possible to immobilize biotinylated small molecules which have the ability  
 
to bind specific oligonucleotides and motifs.
57 
 
 
 
Figure 3.01 Example of a streptavadin-biotin capture biosensor chip
58 
 
 To date, much is already known about the bithiazole DNA binding domain of  
 
bleomycin as well as its binding specificity and strong preference for 5ʹ-CT and 5ʹ-CG  
 
rich sequences.
10,17 
Previous studies done to identify DNA binding motifs of bleomycin  
 
have been based primarily on cleavage assays of oligonucleotides and the investigation  
 
and characterization of the degradation products produced. However, there has been little  
 
supporting literature
59,60
 reporting the use of SPR as a tool to delineate such a unique  
 
DNA binding profile (Figure 3.02). 
 
 When binding constant determination is possible within the parameters of the two  
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ligands (and instrumentation limits), the resulting output is a sensorgram. When the two  
 
ligands interact through a microflow system an increase in SPR signal, expressed in  
 
“response units (RU)” is observed. When the complex of the two ligands becomes  
 
disassociated a decrease in RU is observed. From the two observable events, the on-(ka)  
 
and off-(kd) rates as well as the equilibrium constant (KD) can be calculated. The valuable  
 
kinetic information obtained can provide mechanistic conclusions about the system. 
 
 
 
Figure 3.02 A typical sensorgram model (As output from a typical biacore instrument) 
 
 The antitumor activity of bleomycin is understood  to derive its ability to cleave  
 
DNA,
61
 and possibly RNA as well.
62-65 
Until very recently, almost all studies of BLM- 
 
mediated  DNA cleavage were carried out using an excess of metalloBLM. However, one  
 
unique characteristic of bleomycin is its atypically low clinical dose (~5 µmol).  
 
Accordingly, it seemed logical to inquire whether the preferential binding motifs  
 
observed previously (where a large excess of bleomycin was present) were unchanged  
 
when a large excess of DNA relative to bleomycin was employed and studied. 
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3.02 Results 
 
Many derivatized apo-(metal free) BLMs and metalloBLMs were prepared for the  
 
study of DNA binding dynamics, in accordance with previous literature for  
 
functionalizing BLMs.
66
 Usually, the final product was obtained in no more than two  
 
steps and in good yield (Schemes 3.01-3.05).
 
Often the necessary transformations  
 
occurred in a single step (many metalloBLMs) and in quantitative yield following simple  
 
mixing and lyophilization (Scheme 3.01). Functionalization of BLM A5 generally  
 
proceeded by generating the Cu(II) conjugate, thereby leaving a single reactive exposed  
 
amine at the C-terminus. This was the methodology followed for N-acetyl BLM A5  
 
presented in Scheme 3.02, as well as for the biotinylation of several BLMs (Scheme  
 
3.04). N-acetylation of BLM A2 required no such chelation to a Cu(II), as the amine  
 
contained in the β-aminoalanineamide side chain of the pyrimidoblamic acid moiety (one  
 
of the N-terminal metal ion binding sites contained within bleomycin), was the free  
 
amine intended to undergo the acetylation (Schemes 3.02 and 3.05). Additionally the  
 
synthesis of the N-biotinyloxysuccinimide 3.14 (needed for the biotin functionalization of  
 
BLM A5) is shown below in Scheme 3.03.  
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Scheme 3.01 General synthetic scheme employed for several metalloBLMs 
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Scheme 3.02 Synthetic route employed for N-acetyl BLM A5 
 
 
 
Scheme 3.03 Synthetic route employed for the N-biotinyloxysuccinimide
66
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Scheme 3.04 Synthetic route employed for the preparation of biotinylated BLMs  
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Scheme 3.05 Synthetic route employed for N-acetyl BLM A2 
 
 Previous studies, including the microbubble‒BLM experiments67 lacked the  
 
ability to quantitatively measure nucleic acid binding by BLM. Binding of BLM to B- 
 
form DNA is accompanied by fluorescence quenching of the bithiazole moiety.
68,69  
 
However this potential method for quantification has not been independently validated  
 
and does not predict binding affinities for non-B-form DNAs.
70,71 
To overcome the  
 
quantification obstacle and permit assessment of the dynamics of BLM binding to  
 
selected hairpin DNAs (whose sequences were chosen for strong BLM binding),
72-74
  
 
surface plasmon resonance (SPR) was employed. This method has been the choice of  
 
many studies to assess the interaction of other ligands with nucleic acid moieties.
75-77
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 The primary focus of this SPR study was hairpin DNA 2 (Figure 3.203, which  
 
was shown in a previous study to bind BLM A5 more strongly than most of the other  
 
hairpin DNAs investigated.
73,74
 
 
 
 
 
Figure 3.03 A) Sequence-selective cleavage of [5′-32P]-end labeled 64-nt hairpin DNA 2 
by BLM A5. Lane 1, radiolabeled 2 alone; lane 2, 20 μM Fe
2+; lane 3, 20 μM BLM A5; 
lane 4, 5 μM Fe(II)•BLM A5; lane 5, 10 μM Fe(II)•BLM A5; lane 6, 20 μM Fe(II)•BLM 
A5; lane 7, G+A lane. B) Sequence-selective cleavage of [3′-
32P]-end labeled 64-nt 
hairpin DNA 2 by BLM A5. Lane 1, radiolabeled 2 alone; lane 2, 10 μM Fe
2+; lane 3, 10 
μM BLM A5; lane 4, 1 μM Fe(II)•BLM A5; lane 5, 5 μM Fe(II)•BLM A5; lane 6, 10 μM 
Fe(II)•BLM A5; lane 7, G+A lane. 
 
 The 5ʹ-32P end-labeled DNA 2 exhibited cleavage at numerous sites when treated  
 
with Fe(II)•BLM A5 and Fe(II)•deglycoBLM A5. The cleavage sites for the two BLM  
 
congeners were quite similar,
74,75 but Fe(II)•BLM A5 was found to be more potent as a  
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DNA cleaving agent. Summarized in Figure 3.03 are the sites of cleavage by  
 
Fe(II)•BLM A5 of the same hairpin DNA, radiolabeled at the 3ʹ- and 5ʹ- ends. Treatment  
 
of the same 5ʹ-32P end-labeled hairpin DNA with Fe(II)•BLM B2 gave similar results,  
 
with similar cleavage intensities seen with Fe(II)•BLM A5.
78 
 
 Hairpin DNA 2 was attached to a BIAcore sensor chip through a biotin moiety  
 
that was connected through a six carbon alkyl chain tether at the 5ʹ-end.79 The alkyl tether  
 
enables a more “free-flowing” DNA due to its flexibility and one that more sensibly  
 
mimics a purely solution phase interaction. It is also conveniently commercially available  
 
as a feature in custom oligonucleotide functionalizations. Initially the KA values obtained  
 
for Fe(III)•BLM B2, Fe(III)•deglycoBLM A5, and BLM A5 were measured to assess the  
 
relative affinities for metalloBLMs , that were incapable of DNA cleavage. For all of the  
 
BLM samples, a single strong binding mode was noted.  When the BLM samples were  
 
measured at 25 
o
C and 10 mM NaCl, the KA values were found to be approximately 3.2 x  
 
10
6
, 3.0 x 10
6
 and 1.5 x 10
6 
M
-1
, respectively, for the above BLMs. Therefore the relative  
 
affinities of these metalloBLMs for hairpin DNA 2 (BLM B2 ≈ deglycoBLM A5 > BLM  
 
A5) was not in the same order as the respective potencies of cleavage of the DNA by the  
 
corresponding Fe(II) derivatives (BLM B2 ≈ BLM A5 > deglycoBLM A5).  However the  
 
actual cleavage sites for all three BLMs were quite similar.  
 
 These experiments establish that the relative efficiency of cleavage of a strongly  
 
bound hairpin DNA by a metalloBLM is not controlled simply by BLM‒DNA affinity.  
 
This observation is also supported by the finding that there was a single strong binding  
 
site for Fe(III)•BLM B2 but there were multiple cleavage sites observed, two of which  
 
involved strong cleavage. BLM B2 has been shown to cleave chromosomal DNA  
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efficiently in cultured human cell lines.
80
 The interaction of BLM B2 with DNA 2 was  
 
characterized more carefully. An SPR sensorgram shown in Figure 3.04 summarizes the  
 
interaction at 25 and 10 mM NaCl concentrations, respectively. 
 
 
 
 
Figure 3.04 SPR sensorgrams for the interaction of Fe(III)•BLM B2 with DNA 2 at 25 
mM (left panal) and 10 mM (right panel) NaCl concentrations at 25 oC. The individual 
sensorgrams (colored) represent responses at BLM B2 concentrations of 50, 75, 100, 150, 
200, 250, 300, 400 and 500 nM (bottom to top). Global kinetic fit (black solid lines) with 
a 1:1 binding model was performed using BIAcore T200 Evaluation Software to obtain 
kinetic association and dissociation rate constants. 
 
 Shown in Figure 3.22 is an SPR sensorgram of the binding of Fe(III)•BLM B2 to  
 
immobilized hairpin DNA 2 at 25 
o
C. The concentrations of metalloBLM employed were  
 
50-500 nM. The KA calculated for this interaction was found to be 3.9 x 10
6
 M
-1
. The on- 
 
rate ka was determined to be 0.074 s
-1
. A summary of the data calculated at the two salt  
 
concentrations used and two temperatures is displayed in Table 1. Similar results for the  
 
on-rates increased 2.5‒3-fold at the higher temperature (25 oC). Accordingly KA was ~3  
 
times larger at the lower temperature (15 
o
C) due to the change in off-rate. Small,  
 
consistent changes in measured parameters were a direct result of the changes in salt  
 
concentrations (10 mM-25 mM NaCl).  
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Table 3.01 Binding of Fe(III)•BLM B2 to DNA 2
a
 
________________________________________________________________________ 
   ka (M
-1s-1)            kd (s
-1)       KA (M
-1)            KD (nM)            KA (M
-1, steady-state) 
  
 ____________________________________________________________________________________________________________________________________________ 
15 °C  
10 mM  NaCl  1.78 × 105 0.017        10.5 × 106                  95           9.4 x 106 ; 0.20 x 106 
25 mM  NaCl  3.45 × 105 0.023    15.2 × 106     66           9.3 x 106 ; 0.38 x 106 
 
25 °C 
10 mM  NaCl  1.35 × 105 0.042    3.2 × 106    312           3.1 × 106  
25 mM  NaCl  2.85 × 105 0.074    3.9 × 106    256           3.4 × 106  
 
a50, 75, 100, 150, 200 and 250 nM concentrations of Fe (III)•BLM B2.  Quite similar results 
were obtained when higher (300 – 500 nM) concentrations were employed. Based on reproducibility of results, the 
errors in the strong binding constants and kinetics constants are ±15% and close to 50% for the weaker binding 
constants.  
________________________________________________________________________ 
 
 The structural components in hairpin DNA 2 or Fe(III)•BLM B2 which cause  
 
these changes in affinity and dynamics of interaction are not entirely clear at this time but  
 
could be revealed by further alterations in the BLM congeners or the hairpin DNA itself.  
 
An unanticipated result was the dramatically lower affinity of apo-(metal free) BLM B2  
 
for DNA 2 (KA = 2.2 x 10
4
 M
-1
 at 10 mM NaCl and 25 
o
C). However this result was in  
 
qualitative agreement with a previous study that used fluorescence quenching of the  
 
bithiazole (DNA binding domain) of bleomycin as an end point for assessing DNA  
 
binding in the presence of Fe(II) and Cu(II).
69
 
 
 As is presented in Figure 3.03, for Fe(III)•BLM B2, the Fe(II)•BLMs investigated  
 
each cleaved hairpin DNA 2 at multiple sites, and with somewhat different efficiencies.  
 
The cleavage sites seen in Figure 3.03 were obtained under single hit kinetic conditions;  
 
therefore it is logical to conclude that it may be possible for metalloBLMs to bind hairpin  
 
DNAs in multiple different ways, each of which would give a distinct DNA cleavage  
 
pattern. In order to assess whether it is possible to detect more than one binding mode by  
 
SPR, the data obtained from  the sensorgrams was subjected to a steady-state analysis.  
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This was done using additional concentrations of Fe(III)•BLM B2 up to 1 µM (Figure  
 
3.03) The Figure below shows the SPR equilibrium binding plots for Fe(III)•BLM B2  
 
with DNA 2 at two salt concentrations (10 and 25 mmol) at 25 
o
C. The steady-state  
 
analysis used the same experimental data shown above, but up to a higher concentration  
 
(1 µM). The strong binding constant determined (3.4 x 10
6
 at 25 mM NaCl and 3.1 x 10
6  
 
mM NaCl) and the kinetic binding constant determined (3.9 x 10
6
 at 25 mM NaCl and 3.2  
 
x 10
6
 at 10 mMol NaCl) were in good agreement. 
 
 
 
Figure 3.05 SPR equilibrium binding plots of Fe(III)•BLM B2 with DNA 2 at 10 mM and 
25 mM NaCl concentrations and 25 oC. The steady-state response values were fitted as a 
function of free ligand concentration to a single-site interaction model. The binding 
affinities are listed in Table 3.01. 
 
 Figure 3.06 below displays the SPR equilibrium binding plots for Fe(III)•BLM  
 
B2 and DNA 2 at the two salt concentrations and at 15 
o
C. Comparing the steady-state  
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analysis and experimental data shown above shows that there is good agreement of the  
 
strong binding constant and the kinetic binding constant (3.4 x 10
6
 vs 3.9 x 10
6
 M
-1
 at 25  
 
mM NaCl and 3.2 x 10
6 
vs 3.1 x 10
6
 M
-1 
at 10 mM NaCl).  By using the steady-state  
 
model, it was possible to estimate a value for the second binding mode which was found  
 
to have quite fast kinetics. It was found that the second binding mode was 10-20+ times  
 
weaker than the primary binding mode and could only be determined with a large margin  
 
of error (~40%).The estimated values of the steady-state binding constants for  
 
Fe(III)•BLM B2 and immobilized hairpin DNA 2 at 10 mM NaCl and 15 
o
C were 9.4 x  
 
10
6
 and 0.20 x 10
6
 M
-1
 for the strong and weak binding sites, respectively. Given that  
 
there are multiple cleavage sites observed for Fe•BLM on DNA 2, there probably exist  
 
multiple weaker binding sites for  Fe(III)•BLM B2 as well. However, they have not been  
 
established as it is difficult to achieve saturation and maximum stoichiometry.  
 
 The presence of one strong binding site as well as multiple weaker binding  
 
sites for Fe(III)•BLM B2 was observed for other DNAs in addition to DNA 2, and was  
 
reported previously (Figure 3.06).
72,73 
Shown below, DNAs 4 and 5 exhibited similar  
 
characteristics (a single strong binding site as one or more weaker binding sites. DNA  
 
5 actually showed numerous strong cleavage sites, even though there was only a single  
 
strong binding site expected. 
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Figure 3.06 SPR steady-state equilibrium binding plots of Fe(III)•BLM B2 with different 
DNA sequences at 10 mM NaCl and 15 °C. The steady-state response values were fitted 
as a function of free ligand concentration to a two-site interaction model. The equilibrium 
binding affinities are listed in the inset 
 
 Also shown in a previous study, was evidence that a 16-nt hairpin DNA cleaved  
 
stoichiometrically of Fe(II)•BLM did not undergo significant cleavage in the presence of  
 
an additional one equivalent of some selected, strongly bound 64-nt hairpin DNA.
78
 This  
 
observation suggests that association of BLM with a strongly bound DNA substrate,  
 
effectively precludes the binding to other DNA species. In an attempt to gain further  
 
insight into the mechanistic nature of hairpin DNA 2 cleavage, several competition  
 
experiments in which 
32
P-radiolabeled samples of DNA 2 (or another 16-nt hairpin DNA  
 
of comparable specific activity) were treated with Fe(II)•BLM in the presence of an  
 
unlabeled DNA substrate as a competitor species. As shown in Figure 3.06 above, the  
 
Fe(II)•BLM B2-mediated cleavage of hairpin DNA 2 was minimally affected by the use  
 
of eight additional equivalents of the unlabeled 16-nt DNA. However, the presence of a  
 
single equivalent of DNA 2 precluded cleavage of the radiolabeled 16-nt hairpin DNA.  
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These findings suggest that, even when not bound to the established strong binding sites  
 
of DNA, Fe(II)•BLM must remain in proximity to this DNA. This results in selective  
 
preferential cleavage at weakly bound sites in the same hairpin DNA in spite of available  
 
cleavage sites in another DNA. 
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3.03 Discussion 
 
 
 The characterization of the binding and cleavage by Fe•BLM of a hairpin DNA  
 
substrate, which was selected for strong binding affinity to BLM was successful. The  
 
hairpin DNA is cleaved on both arms by three different BLM species, all with similar  
 
sequence preferences but with different efficiencies. Throughout the above study it was  
 
clearly shown that the relative efficiencies of DNA cleavage do not simply correlate with  
 
relative binding affinities. This indicates that affinity is only one single factor in  
 
understanding and defining the cleavage efficiency of BLM on a DNA substrate. SPR  
 
analysis of BLM binding to the immobilized hairpin DNA has recently permitted the  
 
dynamics of binding to be defined.
56 
 
 In addition to immobilizing the 16-nt hairpin DNA 2 substrate, the system was  
 
also attempted in reverse. The BLMs employed were functionalized with a biotin moiety,  
 
which then allowed the immobilization of the biotinylated-BLM on the SPR sensor chip  
 
(streptavidin derivatized). This change in experimental parameters led to irreproducible  
 
results and very large margins of error. While this approach (having an excess of BLM in  
 
the presence of a DNA substrate) is a traditional model for the study of BLM‒nucleic  
 
acid interaction
16,81-86 
it proved unsuccessful for measuring steady-state binding profiles  
 
of BLM.  
  
 In summary, the binding constants identified by SPR analysis showed that the on- 
 
rate, (ka values) were essentially unchanged when temperature decreased from 25 
o
C to  
 
15 
o
C, while the off-rate (kd values) decreased approximately three fold at both salt  
 
concentrations studied. Both the kinetic and steady-state binding constants were in  
 
agreement and the steady-state analysis allowed for the detection of at least one weaker  
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binding mode for Fe(III)•BLM B2 to hairpin DNA 2 (as well as DNA 4 and DNA 5).  
 
While the mode of binding to DNA by BLM has been studied previously,
85,87-90 
the  
 
dynamics of interaction have not. The work presented herein significantly expands our 
 
understanding of the quantitative parameters and dynamics of BLM binding to DNA  
 
substrates and the overall relationship between DNA binding and cleavage by  
 
metalloBLMs.  
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3.04 Experimental 
  
General Methods: All solvents used were of analytical grade. Anhydrous solvents were  
 
of DriSolv
® 
quality and purchased from VWR. All experiments were run under a dry  
 
nitrogen atmosphere in flame-dried glassware. All other chemicals were purchased from  
 
Aldrich and used without further purification. Flash chromatography was carried out  
 
using Silicycle 200-400 mesh silica gel. Analytical TLC was carried out using 0.25 mm  
 
EM silica gel 60 F250 plates that were visualized by UV irradiation (254 nm). HPLC  
 
separations were performed on an Agilent 1100 series HPLC system using a diode array  
 
detector. The crude products were purified on an Alltech Alltima C18 reversed phase  
 
semi-preparative (250 x 10 mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN  
 
mobile phases. UV-Vis spectrophotometric analysis and quantifications were done using  
 
a Beckman DU Series 500 UV/Vis spectrophotometer equipped with a single cell  
 
module. 
1
H and 
13
C NMR spectra were recorded on a 400 MHz Varian Liquid-State  
 
NMR in chloroform-d (unless otherwise noted). Chemical shifts were reported in parts  
 
per million (ppm, δ) referenced to the residual 1H resonance of the solvent (CDCl3, 7.26  
 
ppm). 
13
C spectra were referenced to the residual 
13
C resonance of the solvent (CDCl3,  
 
77.0 ppm). Splitting patterns were designated as follows: s, singlet; br, broad; d, doublet;  
 
dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectra  
 
were obtained in the Arizona State University CLAS High Resolution Mass Spectrometry  
 
Laboratory or in the Michigan State University Mass Spectrometry Facility. 
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Cu(II)•Bleomycin A5 (3.01). Bleomycin A5 (2.00 mg, 1.39 µmol) of was dissolved  
 
in 495 μL (1.46 µmol) of 2.944 mM aq CuCl2 at 25 
o
C and stirred for 24 h. The solution  
 
was frozen and lyophilized to give Cu(II)•bleomycin A5 (3.01) as a blue solid: yield 2.09  
 
mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1439.5910 (M-Cu)
+
  
 
(C57H89N19O21S2 requires 1439.5922). 
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Cu(II)•Bleomycin A2 (3.02). Bleomycin A2 (2.00 mg (1.41 µmol) of was dissolved  
 
in 504 μL (1.48 mmol) of 2.944 mM aq CuCl2 at 25 
o
C and stirred for 24 h. The solution  
 
was frozen and lyophilized to give Cu(II)•bleomycin A2 (3.02) as a blue solid: yield 2.09  
 
mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1414.5180 (M-Cu)
+
  
 
(C55H84N17O21S3 requires 1414.5184). 
 
 
 
Copper(II)•Bleomycin B2 (3.03). Bleomycin B2 (2.00 mg  1.40 µmol) of was  
 
dissolved in 504 μL (1.48 µmol) of 2.944 M aq CuCl2 at 25 
o
C and stirred for 24 h. The  
 
solution was frozen and lyophilized to give Cu(II)•bleomycin B2 (3.03) as a blue solid:  
 
yield 2.09 mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1488.4930 (M-Cu)
+
  
 
(C55H85N20O21S2 requires 1488.4930). 
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Fe(III)•Bleomycin A2 (3.04). Bleomycin A2 (2.00 mg, 1.41 µmol) of was treated  
 
with 504 μL (1.48 µmol) of a 2.944 mM aq FeCl3·6H2O at 25 
o
C and stirred for 24 h.  
 
The solution was lyophilized to give Fe(III)•bleomycin A2 (3.04) as a yellow solid: yield  
 
2.08 mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1414.5180 (M-Fe)
+
  
 
(C57H86N17O22S3 requires 1414.5184). 
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Fe(III)•Bleomycin A5 (3.05). Bleomycin A5 (2.00 mg, 1.34 µmol) of was treated  
 
with 495 μL (1.46 µmol) of a 2.944 mM aq FeCl3·6H2O at 25 
o
C for 24 h, frozen and  
 
then lyophilized to give Fe(III)•Bleomycin A5 (3.05) as a yellow solid: yield 2.08 mg  
 
(quant.) mass spectrum (MALDI-TOF ES
+
), m/z 1495.5280 (M-Fe)
+
  
 
(C57H89N19O21S2 requires 1495.5271). 
 
 
 
 
Fe(III)•Bleomycin B2 (3.06). Bleomycin B2 (2.00 mg, 1.40 µmol) was treated with 
 
500 μL (1.47 µmol) of 2.944 mM aq FeCl3·6H2O at 25 
o
C for 24 h. The solution was  
 
frozen and then lyophilized to give Fe(III)•bleomycin A2 (3.06) as a yellow solid: yield  
 
2.08 mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1414.5180 (M-Fe)
+
  
 
(C57H86N17O22S3 requires 1414.5184). 
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Deglycobleomycin A5 (3.07). Cu(II)•deglycobleomycin A5 (4.00 mg, 3.52 µmol) was  
 
treated with 0.5 mL of 15% aq EDTA at 25 
o
C for 24 h and then lyophilized.  
 
The reaction mixture was purified on an Alltech C18 reversed phase semi-preparative (250  
 
x 10 mm, 5 μm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear  
 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 65:35 0.1% aq TFA‒CH3CN)  
 
over a period of 35 min at a flow rate of 3 mL/min. Fractions containing the desired  
 
product eluted at 14.4 min and were collected, frozen and lyophilized to afford a colorless  
 
solid: yield 2.15 mg (57%); mass spectrum (MALDI-TOF ES
+
), m/z 1072.4797 (M)
+
  
 
(C44H68N18O10S2 requires 1072.4807). 
 
 
 
 
Fe(III)•Deglycobleomycin A5 (3.08). Deglycobleomycin A5 (1.76 mg, 1.64 µmol)  
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was treated with 583 μL (1.72 µmol) of a 2.944 mM aq solution of FeCl3·6H2O at  
 
25 
o
C for 24 h. The solution was frozen and then lyophilized to give  
 
Fe(III)•Deglycobleomycin A5 (3.08)  as a yellow solid: yield 1.86 mg (quant.); mass  
 
spectrum (MALDI-TOF ES
+
), m/z 1072.4850 (M-Fe)
+
 (C44H68N18O10S2 requires  
 
1072.4837). 
 
 
 
 
 
N-acetyl bleomycin A2 (3.09). To a stirred solution of 4.50 mg (3.20 µmol) of  
 
bleomycin A2 in 1.0 mL H2O was added 1.5 mg (9.50 µmol) of N-acetoxysuccinimide 
 
and a catalytic amount of Na2CO3 at 25 
o
C, the reaction mixture was stirred for 12 h. The  
 
reaction mixture was purified on an Alltech C18 reversed phase semi-preparative (250 x  
 
10 mm, 5 μm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear  
 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 63:37 0.1% aq TFA‒CH3CN)  
 
over a period of 20 min at a flow rate of 3 mL/min. Fractions containing the desired  
 
product eluted at 15.2 min and were collected, frozen and lyophilized to afford a colorless  
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solid: yield 2.34 mg (50%); mass spectrum (MALDI-TOF ES
+
), m/z 1456.5280 (M-Fe)
+
  
 
(C57H86N17O22S3 requires 1456.5290). 
 
 
 
Cu(II)•N-acetyl bleomycin A5 (3.10). To a stirred solution of 11.0 mg (7.30 µmol)  
 
of Cu(II)•bleomycin A5 (3.01)  in 2.0 mL of 1 M phosphate buffer pH = 8.2 was added  
 
3.50 mg (22.0 µmol) of N-acetoxysuccinimide at 25 
o
C, the reaction mixture was  
 
stirred for 12 h. The reaction mixture was purified on an Alltech C18 reversed phase semi- 
 
preparative (250 x 10 mm, 5 μm) HPLC column using 0.1% aq TFA and CH3CN mobile  
 
phases. A linear gradient was employed (99:1 0.1% aq TFA‒CH3CN → 63:37 0.1% aq  
 
TFA‒CH3CN) over a period of 20 min with a flow rate of 3 mL/min. Fractions  
 
containing the desired product eluted at 15.1 min and were collected, frozen and  
 
lyophilized to afford a blue solid: yield 4.84 mg (45%); mass spectrum (MALDI-TOF  
 
ES
+
), m/z 1444.5344 (M-Fe)
+
 (C59H91N19O22S2 requires 1444.5323). 
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Fe(III)•N-acetyl bleomycin A2 (3.11). N-acetyl BLM A2 (2.09), (0.51 mg, 0.35 µmol)  
 
was treated with 125 µL (0.37 µmol) of a 2.944 mM aq FeCl3·6H2O solution at 25 
o
C for  
 
12 h. The mixture was frozen and then lyophilized to afford Fe(III)•N-acetyl bleomycin  
 
A2 (3.11) as a yellow solid: yield 0.53 mg (quant); mass spectrum (TOF ES
+
), m/z  
 
1456.5280 (M-Fe)
+
 (C57H86N17O22S3 requires 1456.5290). 
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N-acetyl bleomycin A5 (3.12). N-acetyl Cu(II)•bleomycin A5 (3.10), 2.00 mg (1.29 
 
µmol) of was treated with 1.5 mL of a 15% aq EDTA solution at 25 
o
C, the reaction  
 
mixture was stirred for 12 h. The crude reaction mixture was purified on an Alltech C18  
 
reversed phase semi preparative (250 x 10 mm, 5 μm) HPLC column using 0.1% aq  
 
TFA and CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA‒ 
 
CH3CN → 63:37 0.1% aq TFA‒CH3CN) over a period of 20 min at a flow rate of 3.0  
 
mL/min. Fractions containing the desired product eluted at 18.3 min and were collected,  
 
frozen and lyophilized to afford a colorless solid: yield 1.91 mg (99%); mass spectrum  
 
(MALDI-TOF ES
+
), m/z 1481.6020 (M
+
) (C59H91N19O22S2 requires 1481.6027). 
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Fe(III)•N-acetyl bleomycin A5 (3.13). N-acetyl bleomycin A5 (3.12), (1.72 mg, 1.16  
 
µmol) of was treated with 413 µL (1.21 µmol) of a 2.944 mM aq FeCl3·6H2O solution at  
 
25 
o
C for 12 h. The reaction mixture was frozen and then lyophilized to give a yellow  
 
solid: yield 1.79 mg (quant); mass spectrum (TOF ES
+
), m/z 1481.6018 (M-Fe)
+
  
 
(C59H91N19O22S2 requires 1481.6027). 
 
 
 
 
 
N-biotinyloxysuccinimide (3.14).
66
 To a stirred solution of 250 mg (1.02 mmol) of (+)- 
 
biotin and 130 mg (1.13 mmol) of N-hydroxysuccinimide in 15 mL of DMF was added  
 
232 mg (1.13 mmol) of DCC at 0 
o
C. The solution was allowed to warm to room  
 
temperature and stirred at 25 
o
C for 24 h. The solution was filtered and the filtrate was  
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concentrated under diminished pressure. The crude product was suspended in hot (~70  
 
o
C) isopropyl alcohol for 20 min and then filtered. The filtrate cooled to room  
 
temperature and was then filtered. The precipitate was collected and crystallized from  
 
DMF‒Et2O to give a colorless solid: yield 171 mg (49%); mp 204-206 
o
C, lit.
66
 mp 212  
 
o
C; 
1
H NMR (DMSO) δ 1.42 (m, 3H), 1.65 (m, 3H), 2.58 (d, 1H, J = 12.4 Hz), 2.67 (t,  
 
3H, J = 7.4 Hz), 2.81 (m, 4H), 3.11 (m, 1H), 4.15 (m, 1H), 4.30 (m, 1H), 6.37 (s, 1H) and  
 
6.43 (s, 1H). 
13
C (DMSO) δ 24.2, 25.4, 27.5, 27.8, 29.9, 55.2, 59.1, 60.9, 162.6, 168.9  
 
and 170.2; mass spectrum (MALDI-TOF), m/z 342.0138 (M+H)
+
 (C14H20N3O5S requires  
 
342.0125). 
 
 
 
Biotinylated Cu(II)•Bleomycin A5 (3.15). To a stirred solution of 6.0 mg (4.0 µmol)  
 
of Cu(II)·Bleomycin A5 (3.02)  in 1.0 mL of 1 M phosphate buffer pH = 8.2 was added  
 
1.63 mg (4.80 µmol) of N-biotinyloxysuccinimide (3.14) at 25 
o
C. The solution was  
 
stirred at 25
 o
C for 12 h. The reaction mixture was purified on an Alltech C18 reversed  
 
phase semi-preparative (250 x 10 mm, 5 μm) HPLC column using 0.1% aq TFA and  
 
CH3CN mobile phases. A linear gradient was employed (99:1 0.1% aq TFA‒CH3CN →  
 
 112   
  
63:37 0.1% aq TFA‒CH3CN) over a period of 20 min at a flow rate of 3 mL/min.  
 
Fractions containing the desired product eluted at 17.0 min and were collected, frozen  
 
and lyophilized to afford a blue solid: yield 2.59 mg (52%); mass spectrum (MALDI- 
 
TOF ES
+
), m/z 1666.6788 ((M+H)-Cu)
+
 (C67H104N21O23S3 requires 1666.6778). 
 
 
 
 
Biotinylated bleomycin A5 (3.16). Biotinylated Cu(II)•bleomycin A5 (3.15), (4.86 mg,  
 
2.80 µmol) was treated with 1.5 mL of 15% aq EDTA and stirred at 25 
o
C for 24 h. 
 
The reaction mixture was purified on an Alltech C18 reversed phase semi-preparative  
 
(250 x 10 mm, 5 μm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A  
 
linear gradient was employed (99:1 0.1% aq TFA‒CH3CN → 63:37 0.1% aq TFA‒  
 
CH3CN) over a period of 20 min with a flow rate of 3 mL/min. Fractions containing the  
 
desired product eluted at 16.7 min and were collected, frozen and lyophilized to afford a  
 
colorless solid: yield 2.25 mg (46%); mass spectrum (MALDI-TOF ES
+
), m/z 1666.6799  
 
(M+H)
+
 (C67H104N21O23S3 requires 1666.6778). 
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Biotinylated Fe(III)•Bleomycin A5 (3.17). Biotinylated BLM A5 (3.16), (2.25 mg, 1.40  
 
µmol) was treated with 481 μL (1.45 mmol) of a 2.944 mM aq solution of FeCl3·6H2O at  
 
25 
o
C and stirred for 12 h. The solution was frozen and then lyophilized to afford a  
 
yellow solid: yield 2.33 mg (quant.); mass spectrum (MALDI-TOF ES
+
), m/z 1666.6789  
 
((M+H)-Fe)
+
 (C67H103N21O23S3 requires 1666.6778). 
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Chapter 4 
 
4.01 Introduction 
 
 Fluorescence microscopy provides an alternative method for studying small  
 
molecule interaction with nucleic acids and/or proteins by measuring light emitted from a  
 
fluorophore. Fluorophores traditionally consist of complex, conjugated ring systems that  
 
become excited when exposed to specific wavelengths of light. Typically in  
 
fluorescence microscopy systems, light is transmitted from a mercury or xenon arc lamp  
 
and is passed through an optical filter which only allows a very select range of  
 
wavelengths (corresponding to the excitation wavelength of the fluorophore) to penetrate  
 
the sample being examined (Figure 4.01). Once the fluorophore becomes excited, it then  
 
relaxes back to its ground state energy by emitting a photon of lower energy (longer  
 
wavelength) than the original excitation energy. The emitted photons are passed through  
 
a second filter to a detector that then renders an image to display.  
 
 
Figure 4.01 Schematic representation of fluorescence microscopy 
 
 Fluorescence microscopy offers many advantages over other traditional methods,  
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not only for the study of molecular interactions but also for general imaging and  
 
diagnostics. This technique uses non-ionizing radiation and, if measured properly, can be  
 
used quantitatively.
91,92
 In addition to its antitumor activity, BLM has shown the ability to  
 
specifically target tumors and has the potential for being a tumor-imaging agent.
93-98  
 
Previous studies in the Hecht lab and others have provided evidence that the disaccharide  
 
moiety (L-gulose-D-mannose) is critical in cancer cell recognition and is possibly critical  
 
for cellular uptake as well (Figure 4.02). Identification of the specific structural elements  
 
of BLM responsible for tumor targeting would allow for the synthesis of analogues with  
 
improved properties, as well as the possibility for selective delivery of otherwise non- 
 
selective drugs to tumor (or otherwise pathogenic) cells. 
 
 
 
Figure 4.02 Highlighted inset of the disaccharide moiety within BLM A5 
 
Previously in the Hecht laboratory it was shown that BLM A5 conjugated to  
 
microbubbles binds selectively to tumor cells.
67 
Traditionally, microbubbles have been  
 
used as ultrasonography contrast agents and more recently have been modified with  
 
specific (cancer and other) cell surface ligands in order to probe ligand‒cell surface  
 
interactions.
99,100 
In a previous study, similar to the SPR studies presented in Chapter 3,  
 
BLM was biotinylated on the C-terminus and bound to commercially produced  
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streptavidin microbubbles. It was then observed that only the BLM-derivatized  
 
microbubbles (but not the streptavidin-derivatized control ones) bound to MCF-7 human  
 
breast carcinoma cells but not to the “normal” MCF-10A human breast cells. It was  
 
shown that BLM A5‒microbubble conjugates exhibited selective binding to specific  
 
tumor cell lines.
67
 In the previous study, the C-terminal amine of BLM was biotinylated  
 
and bound to commercially available streptavidin-derivatized microbubbles. It was  
 
observed that BLM-derivatized microbubbles (and not the streptavidin-derivatized ones)  
 
bound to MCF-7 human breast carcinoma cells but not to the “normal” counterpart;  
 
MCF-10A breast cell line. To delineate the structural elements responsible for this  
 
selective recognition, the same experiment was done using deglycoBLM A5 (a BLM A5,  
 
which lacks the disaccharide moiety). Cellular recognition was not observed for either  
 
cell line (MCF-7 and MCF-10A) indicating the necessity of the disaccharide moiety. To  
 
further investigate the role of the disaccharide moiety in selective tumor cell binding,  
 
fluorescence microscopy was employed. BLM A5 and deglycoBLM A5 were conjugated  
 
to a cyanine dye; Cy5** (Scheme 4.02).  
 
Fluorescence microscopy studies were carried out using similar and analogous  
 
methodology by using BLM A5 and deglycoBLM A5 conjugated to a cyanine dye;  
 
Cy5** (Figure 4.03). Again, the imaging of cancer cells required the presence of the  
 
BLM disaccharide moiety. 
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Figure 4.03 Structures of BLM-Cy5**, deglycoBLM-Cy5**, and BLM disaccharide-
Cy5**.
101.102 
 
 Studies were also employed using simply the disaccharide conjugated through a  
 
linker to Cy5** and a wide variety of cell lines with matched “normal” counterparts were  
 
analyzed (prostate, colon, kidney, pancreas). 
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4.02 Results 
 
 Previous studies established the necessity of the disaccharide moiety for tumor  
 
cell recognition and binding but did not provide the advantage of direct visualization of  
 
the phenomenon as well as the possibility of subsequent quantification. The BLM  
 
disaccharide, comprised of L-gulose linked to 3-carbamoylmannose was synthesized  
 
using a procedure described previously.
78 
The BLM disaccharide was tethered to the dye,  
 
Cy5** through a coupling reaction with a commercially available linker (protected as the  
 
CBz derivative) to give 4.01 in 66% yield (Scheme 4.01). 
 
 
 
 
Figure 4.04 Synthetic route employed for the preparation of BLM disaccharide-Cy5** 
(4.01) 
102 
 
 Deprotection to expose the primary amine followed by deacetylation and  
 
conjugation to Cy5** via treatment with the NHS ester of Cy5** (Cy5**‒NHS) afforded  
 
the BLM disaccharide-Cy5** conjugate 4.01 in 45% yield over the last three steps. The  
 
Cy5** BLM A5 and deglycoBLM A5 dye conjugates were also prepared in an analogous  
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manner and gave the corresponding conjugates in 15% (4.02) and 11% (4.03) respective  
 
yields overall (Scheme 4.02).
67
 
 
 
Scheme 4.01 Synthetic route employed for the preparation of BLM A5-Cy5** and 
deglycoBLM A5 
 
 MCF-7 human breast carcinoma cells and MCF-10A “normal” breast cells were  
 
cultured in 16-well glass chamber slides for 48 h, and then treated with 50 μM of either  
 
BLM-Cy5**, deglycoBLM-Cy5** or the BLM disaccharide-Cy5** at 37 
o
C for 1 h to  
 
allow adequate interaction with the cell surface. The cells were washed twice with PBS  
 
and fixed with a 4% paraformaldehyde solution. Fluorescence imaging was done using a  
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Zeiss Aviovert 200M inverted microscope with 40x oil objective and the appropriate  
 
Cy5(/Cy5**) optical filter set (excitation 651 nm, emission 666 nm). All images were  
 
recorded and target cells counted using a 40× oil objective. For comparative studies, the  
 
exposure time and laser intensity were kept identical for accurate intensity measurements.  
 
Pixel intensity was quantified using AxioVision Release 4.7 version software, and the  
 
mean pixel intensity was generated as gray level.  
 
 Treatment of MCF-7 cells with BLM-Cy5** resulted in significant cellular  
 
interaction and uptake, while no interaction or uptake was observed for the “normal”  
 
MCF-10A cells. The cells were also treated with DAPI in order to image the cell nuclei  
 
(Figure 4.05). 
 
 
Figure 4.05 Uptake of BLM-Cy5** in MCF-7 and MCF-10A breast cells
a 
a 
Images obtained by Dr. Zhiqiang Yu. 
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 After the initial analysis using BLM A5-Cy5** and MCF-7/MCF-10A cell lines,  
 
as were used in previous studies involving microbubbles, investigation of other  
 
fluorescence conjugates, a variety of cell lines and the presence of a metal co-factor (data  
 
not shown) were also studied. A similar experiment was carried out using all three  
 
conjugates with MCF-7/MCF-10A cell lines in addition to incubation with the Cy5**  
 
free dye itself. This served as a negative control to ensure that the cyanine dye itself was  
 
not responsible for facilitating binding or entry into the cell. The results of this study are  
 
summarized in Figure 4.09.  
 
 
Figure 4.06 Uptake of Cy5** conjugates in MCF-7 breast carcinoma cells and MCF-10A 
normal breast cells
a
;
 a 
Images obtained by Dr. Zhiqiang Yu. 
 
 As is clear from Figure 4.06, BLM-Cy5** and BLM disaccharide-Cy5** did not  
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associate with either cell line, as was the case for the negative control (Cy5** free dye).  
 
Additionally, a prostate cancer cell line DU-145 was also compared with its matched  
 
“normal” prostate cell line counterpart PZ-HPV-7. The results from these two cell lines  
 
(Figure 4.08) are qualitatively identical (possibly even showing stronger cellular  
 
interaction) to the results seen above in Figure 4.06. 
 
 
Figure 4.07 Uptake of Cy5** conjugates in DU-145 prostate carcinoma cells and PZ-
HPV-7 normal prostate cells
a
;
 a 
Images obtained by Dr. Zhiqiang Yu.
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 Again, the BLM-A5-Cy5** and BLM disaccharide-Cy5** showed selectivity  
 
for the cancer cell line DU-145 (and not the “normal” prostate cells PZ-HPV-7). The  
 
deglycoBLM A5-Cy5** conjugate showed no interaction with either cell line, as nor did  
 
the negative control (Cy5** free dye). The results in Figures 4.06 and 4.07 are quantified  
 
and summarized in Figure 4.08. 
 
 
 
 
Figure 4.08 Quantification of the binding/uptake of BLM-Cy5**, deglycoBLM-Cy5**, 
BLM disaccharide-Cy5** and Cy5** by MCF-7 and MCF-10A cells (upper panel) or by 
DU-145 and PZ-HPV-7 cells (lower panel) 
 
 The data presented above clearly demonstrate the need for the disaccharide  
 
moiety of BLM for cellular recognition/internalization. The fact that the experiments 
 
presented here showed similar qualitative results for two different matched cell lines is  
 
promising for further studies using other cancerous cell lines. These results also hold  
 
promise for the BLM disaccharide or BLM itself to be used as a diagnostic imaging tool.  
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4.03 Discussion 
 
 Almost all current chemotherapies are limited by side effects resulting from a  
 
lack of tumor cell selectivity. Shown in this study is an uncomplicated disaccharide,  
 
which has the ability to differentiate between tumor cells and normal cells. In addition to  
 
studying the Cy5** conjugates, several other commercially available (cyanine and  
 
otherwise) dyes were tried. The scope of the dyes available was defined by the need for  
 
easy functionalization and attachment, fluorescence range, quantum yield and the need to  
 
avoid auto-fluorescence when imaging fixed cells). Cy5** gave the most reproducible  
 
results and was used to synthesize the conjugates needed. Cy5** has a maximum  
 
absorbance of 651 nm and, therefore, did not contribute to auto-fluorescence during fixed  
 
cell imaging experiments. 
 
 Initial experiments were also done using the Cu(II) chelates of both the BLM A5- 
 
Cy5** and deglycoBLM A5-Cy5** conjugates and preliminary observations suggested  
 
markedly increased cellular interaction and uptake (of only the disaccharide containing  
 
BLM A5 conjugate and not the deglycoBLM A5 conjugate nascent the disaccharide  
 
moiety, results not shown). This strongly suggests that the binding of a metal cofactor  
 
and, either the subsequent change in secondary structure of BLM or the increase in  
 
overall positive character (or both) further facilitates cellular recognition and increased  
 
uptake into cells. Additionally these studies also displayed a similar trend in cancer cell  
 
line selectivity. This could possibly be a result of a particular secondary structure, that  
 
results in the disaccharide moiety being more readily accessible to cell surface receptors.  
 
 Given the uncomplicated nature of the disaccharide and its ability to selectively  
 
bind to cancer cells, its potential for use in cancer diagnosis, imaging and treatment is an  
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intriguing possibility. A cobalt derivative of BLM has been shown previously to  
 
successfully image brain tumor.
103
 The use of the disaccharide modified by a radiolabel  
 
or a contrast agent could prove a more efficient approach to imaging tumors.
104
  
 
Attachment of the disaccharide to otherwise non-selective chemotherapeutic agents may  
 
allow a “magic-bullet” approach to future chemotherapy treatments.  
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4.04 Experimental 
  
General Methods: All solvents used were of analytical grade. Anhydrous solvents were  
 
of DriSolv
® 
quality and purchased from VWR. All experiments were run under a dry  
 
nitrogen atmosphere in flame-dried glassware. All other chemicals were purchased from  
 
Aldrich and used without further purification. Flash chromatography was carried out  
 
using Silicycle 200-400 mesh silica gel. Analytical TLC was carried out using 0.25 mm  
 
EM silica gel 60 F250 plates that were visualized by UV irradiation (254 nm). HPLC  
 
separations were performed on an Agilent 1100 series HPLC system using a diode array  
 
detector. The crude products were purified on an Alltech Alltima C18 reversed phase  
 
semi-preparative (250 x 10 mm, 5 μm) HPLC column using aq 0.1% TFA and CH3CN  
 
mobile phases. UV-Vis spectrophotometric analysis and quantifications were done using  
 
a Beckman DU Series 500 UV/Vis spectrophotometer equipped with a single cell  
 
module. 
1
H and 
13
C NMR spectra were recorded on a 400 MHz Varian Liquid-State  
 
NMR in chloroform-d (unless otherwise noted). Chemical shifts were reported in parts  
 
per million (ppm, δ) referenced to the residual 1H resonance of the solvent (CDCl3, 7.26  
 
ppm). 
13
C spectra were referenced to the residual 
13
C resonance of the solvent (CDCl3,  
 
77.0 ppm). Splitting patterns were designated as follows: s, singlet; br, broad; d, doublet;  
 
dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectra  
 
were obtained in the Arizona State University CLAS High Resolution Mass Spectrometry  
 
Laboratory or in the Michigan State University Mass Spectrometry Facility. 
 
Cell Growth Conditions.  MCF-7 cells (ATCC HBT-22) were grown in RPMI 1640  
 
(Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (HyClone, South  
 
Logan, UT) and 1% penicillin‒streptomycin mix antibiotic supplement (Cellgro,  
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Manassas,VA). MCF-10A cells (ATCC CRL-10317) were grown in MEGM (Invitrogen,  
 
Grand Island, NY) supplemented with 100 ng/mL cholera toxin (Sigma-Aldrich) and 1%  
 
penicillin‒streptomycin mix antibiotic supplement. DU-145 (ATCC HTB-81) and PZ- 
 
HPV-7 (ATCC CRL-2221) prostate cells were grown in MEM (Gibco, Grand Island,  
 
NY) supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin- 
 
streptomycin mix antibiotic supplement. Cell lines were maintained at 37 °C under a  
 
humidified atmosphere of 5% CO2 and 95% air. 
 
Fluorescence microscopy.  Fluorescence images were obtained using a Zeiss Axiovert  
 
200M inverted microscope fitted with an AxioCam MRm camera equipped with a 300-w  
 
xenon lamp (Sutter, Novato, CA), Cy5 cyanine filter (Chroma, Bellows Falls, VT).  
 
Adherent cancer cells were grown on 16-well Lab-Tek glass chamber slides at a cell  
 
density of 5000 cells/well (Thermo Scientific, Waltham, MA) at 37 °C for 48 h. Cells  
 
were rinsed twice with phosphate buffered saline (PBS) when the cell confluence was  
 
about 70%, then the medium was replaced with RPMI 1640 (no phenol red). The dye- 
 
labeled conjugates were subsequently added to the final desired concentrations. The cells  
 
were incubated at 37 °C for 1 h, washed with PBS, then fixed with 4% paraformaldehyde  
 
at 37 °C for 5 min. Finally the slide was mounted with Prolong Antifade Gold reagent  
 
with DAPI (Invitrogen), then covered with a glass coverslip and dried for 24 h before  
 
fluorescence microscope imaging analysis. All images were recorded and target cells  
 
counted using a 40× oil objective. For comparative studies, the exposure time and laser  
 
intensity were kept identical for accurate intensity measurements. Pixel intensity was  
 
quantified using AxioVision Release 4.7 version software, and the mean pixel intensity  
 
was generated as gray level.  
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Bleomycin-Cy5** (4.01). To a solution containing 0.8 mg (0.5 μmol) of Cu(II)•BLM A5  
 
(3.01) in 500 μL of 0.2 M sodium phosphate, pH 8.2, at room temperature was added 0.3  
 
mg (0.3 μmol) of Cy5** carboxylic acid succinimidyl ester. The reaction mixture was  
 
swirled overnight at room temperature in the dark and the crude reaction mixture was  
 
purified on an Econosil C18 reversed phase semi-preparative (250 x 10 mm, 10 μm)  
 
HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear gradient was  
 
employed (99:1 0.1% aq TFA‒CH3CN → 35:65 0.1% aq TFA‒CH3CN) over a period  
 
of 45 min at a flow rate of 3 mL/min. Fractions containing the desired product eluted at  
 
20.8 min and were collected, frozen and lyophilized to afford a blue powder. The crude  
 
product was dissolved in 15% aq EDTA and stirred overnight at room temperature. The  
 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 ×  
 
10 mm,10 μm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear  
 
gradient was employed (99:1 0.1% aq TFA‒CH3CN → 35:65 0.1% aq TFA‒CH3CN)  
 
over a period of 45 min at a flow rate of 3 mL/min. Fractions containing the desired  
 
product eluted at 20.9 min and were collected, frozen, and lyophilized to give bleomycin  
 
A5-Cy5** (4.01) as a light colored solid: yield 120 μg (15% over two steps); mass  
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spectrum (TOF ESI), m/z 2308.8036 (M+) (C95H138N21O34S6 requires 2308.8049). 
 
 
 
 
 
Deglycobleomycin A5-Cy5** (4.02). To a solution containing 0.9 mg (0.8 μmol) of  
 
Cu(II)•deglycoBLM A5 (3.06) in 1.0 mL of 0.2 M sodium phosphate, pH 8.0, at room  
 
temperature was added 0.3 mg (0.3 μmol) of Cy5** carboxylic acid succinimidyl ester.  
 
The reaction mixture was swirled overnight at room temperature and the crude reaction  
 
mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm,   
 
10 μm) HPLC column using 0.1% aq TFA and CH3CN mobile phases. A linear gradient  
 
was employed (99:1 0.1% aq TFA‒CH3CN → 35:65 0.1% aq TFA‒CH3CN) over a  
 
period of 45 min at a flow rate of 3 mL/min. Fractions containing the desired product  
 
eluted at 21.5 min and were collected, frozen and lyophilized to afford a blue powder.  
 
The crude product was dissolved in 15% aq EDTA and stirred overnight at room  
 
temperature. The reaction mixture was purified on an Econosil C18 reversed phase  
 
semipreparative (250 x 10 mm, 10 μm) HPLC column using 0.1% aq TFA and CH3CN  
 
mobile phases. A linear gradient was employed (99:1 0.1% aq TFA‒CH3CN → 35:65  
 
0.1% aq TFA‒CH3CN) over a period of 45 min at a flow rate of 3 mL/min. Fractions  
 
 130   
  
containing the desired product eluted at 21.3 min and were collected, frozen, and  
 
lyophilized to give deglycoBLM-Cy5** (4.02) as a light colored solid: yield 75 μg (11%  
 
over two steps); mass spectrum (TOF ESI), m/z 1941.6907 (M+) (C82H117N20O23S6  
 
requires 1941.6925). 
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